N;SPECIES_MDR1;NAME;CAS;SMILES;PARSED_SMILES;SUBST_SCORE;SUBST_DATA;INHIB_SCORE;INHIB_SCORE_TYPE;INHIB_DATA;INHIB_REF;EXPERIMENT;COMMENT;REFERENCE;INDUCER_SCORE;TARGET;class
5157;"Rat; Human";4-Aminomethylbenzoate;56917;O=C(O)c1ccc(cc1)CN;O=C(O)C1=CC=C(C=C1)CN;0.0;;0.0;100uM;IC50=6.8-37mM;D-Phe-L-Gln;Xenopus laevis oocyte ; inhibition of D-Phe-L-Gln ; Meredith, D et al, J.Physiol. (1998) 512, 629-634;;PEPT1;0
5158;Human;4-Aminophenylacetate;1197553;O=C(O)Cc1ccc(N)cc1;O=C(O)CC1=CC=C(C=C1)N;1.0;~10*Km of dipeptides;;100uM;;;Xenopus laevis oocyte ; inhibition of D-Phe-L-Gln ; Meredith, D et al, J.Physiol. (1998) 512, 629-634;;PEPT1;1
5161;Human;Ala-Ala;1948318;NC(C)C(NC(C)C(O)=O)=O;NC(C)C(NC(C)C(O)=O)=O;1.0;"Km=0.16mM (LL isomer. While Km=0.80mM for DL; Km=6.12mM for LD; Km>25mM for DD); EC50=0.08mM";1.0;100uM;"IC50=63mkM; >80% at 10mM; Ki=140mkM (Ki=2.1mM for DL and Ki=4.2mM for LD isomers); IC50=0.25mM";"Glycylsarcosine; Valacyclovir; Glycylsarcosine; Glycylsarcosine";"PEPT1-expressing CHO cell; MDCK-PEPT1";"inhibition of Gly-Sar uptake (Gly-Sar: 25000 mkM); inhibition of VACV uptake (VACV: 20 mkM, Ala-Ala: 10000 mkM); inhibition of Gly-Sar uptake (10mkM); efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM)";"K. M. Covitz, Pharm Res (1996) 13, 1631-4; A. Guo, J Pharmacol Exp Ther (1999) 289, 448-54; F.Doring et al, J Clin Invest (1998) 15,2761-67; A.Biegel et al, J Med Chem(2005),48(13), 4410-9; B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44";;PEPT1;1
5162;Human;Ala-Asp;20727655;NC(C)C(NC(CC(O)=O)C(O)=O)=O;NC(C)C(NC(CC(O)=O)C(O)=O)=O;1.0;EC50=0.23mM;1.0;100uM;"Ki=78mkM; Ki=260mkM; IC50=0.45mM";"Glycylsarcosine; Glycylsarcosine; Glycylsarcosine";"PEPT1-expressing HeLa cell; Caco-2; MDCK-PEPT1";"inhibition of Gly-Sar uptake; inhibition of Gly-Sar uptake (10mkM); efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM)";"S. Ramamoorthy, Biochim Biophys Acta (1995) 1240, 1-4; S.Gebauer et al, J Med Chem (2003), 46(26), 5725-34; B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44";;PEPT1;1
5163;Human;Ala-Lys;5051069;NC(C)C(NC(CCCCN)C(O)=O)=O;NC(C)C(NC(CCCCN)C(O)=O)=O;1.0;EC50=0.22mM;0.8;100uM;"Ki=117mkM; Ki=210mkM; IC50=0.28mM";"Glycylsarcosine; Glycylsarcosine";"PEPT1-expressing HeLa cell; MDCK-PEPT1";"inhibition of Gly-Sar uptake; inhibition of Gly-Sar uptake (10mkM); efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM)";"S. Ramamoorthy, Biochim Biophys Acta (1995) 1240, 1-4; A.Biegel et al, J Med Chem(2005),48(13), 4410-9; B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44";;PEPT1;1
5164;Human;Ala-Pro;3918954;NC(C)C(N1C(C(O)=O)CCC1)=O;NC(C)C(N1CCCC1C(O)=O)=O;1.0;def.;0.5;100uM;"8% at 10mM; Ki=5-30mM; Ki=0.15mM";"Glycylsarcosine; Glycylsarcosine; Glycylsarcosine";"PEPT1-expressing HeLa cell; Caco-2; Caco-2";"inhibition of Gly-Sar uptake (Gly-Sar: 20 mkM, Ala-Pro: 10000 mkM); inhibition of Gly-Sar uptake (10mkM); inhibition of Gly-Sar uptake (10mkM)";"R. Liang, J Biol Chem (1995) 270, 6456-63; A.Biegel et al, J Med Chem(2005),48(13), 4410-9; S.Gebauer et al, J Med Chem (2003), 46(26), 5725-34";;PEPT1;1
5165;Human;Ala-Pro-Gly;36301969;NC(C)C(N1C(C(NCC(O)=O)=O)CCC1)=O;NC(C)C(N1CCCC1C(NCC(O)=O)=O)=O;1.0;def.;0.5;100uM;9% at 10mM;Glycylsarcosine;PEPT1-expressing HeLa cell ;inhibition of Gly-Sar uptake (Gly-Sar: 20 mkM, Ala-Pro-Gly: 10000 mkM) ;R. Liang, J Biol Chem (1995) 270, 6456-63 ;;PEPT1;1
5167;Human;Amoxicillin;26787780;O=C(O)[C@@H]2N3C(=O)[C@@H](NC(=O)[C@@H](c1ccc(O)cc1)N)[C@H]3SC2(C)C;O=C(O)[C@H]1C(S[C@@H]2[C@@H](C(N12)=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)(C)C;1.0;" + (review)[Zhang]; + (low affinity substrate)[Li]";0.0;100uM;"85.7% - 62.9% at 10mM; Ki=>10mM";"Cefadroxil; Glycylsarcosine";"Caco-2; MDCK-PEPT1";"inhibition of Cefadroxil uptake (apical pH 5.5 and 6.5, Cefadroxil: 1000 mkM, Amoxicillin: 10000 mkM) ; inhibition of Gly-Sar uptake (pH6.0); transport";"U. Wenzel, J Pharmacol Exp Ther (1996) 277, 831-9; P. Luckner, Eur J Pharm Biopharm (2005) 59, 17-24; L.Zhang et al, Mol. Pharm (2006), 3(1) 62-69; M.Li et al, Drug Metab Dispos (2006), 34(4), 547-555";;PEPT1;1
5168;Human;Ampicillin;33604216;O=C(O)[C@@H]2N3C(=O)[C@@H](NC(=O)[C@@H](c1ccccc1)N)[C@H]3SC2(C)C;O=C(O)[C@H]1C(S[C@@H]2[C@@H](C(N12)=O)NC(=O)[C@@H](C3=CC=CC=C3)N)(C)C;1.0;" + [Bretschneider]; + (review)[Zhang]";0.0;100uM;"50% at 10mM; Ki=14.5mM; IC50=47.4mM";"Valacyclovir; Glycylsarcosine; Glycylsarcosine";"PEPT1-expressing CHO cell; Caco-2";"inhibition of VACV uptake (VACV: 20 mkM, Ampicillin: 10000 mkM); inhibition of Gly-Sar uptake (pH6.0); NB: possibly paracellular transport!!";"A. Guo, J Pharmacol Exp Ther (1999) 289, 448-54; P. Luckner, Eur J Pharm Biopharm (2005) 59, 17-24; L.Zhang et al, Mol. Pharm (2006), 3(1) 62-69; B.Bretschneider et al, Pharm Res (1999) 16, 55-61";;PEPT1;1
5169;Human;Asp(OBzl)-Sar;197895628;NC(CC(OCc1ccccc1)=O)C(N(C)CC(O)=O)=O;NC(CC(OCC1=CC=CC=C1)=O)C(N(C)CC(O)=O)=O;0.0; - [Taub];1.0;100uM;IC50=14mkM;Glycylsarcosine;Caco-2;inhibition of Gly-Sar uptake; Taub, M. E. et al, Int. J. Pharm. (1997) 156, 219-228;;PEPT1;0
5170;Human;Asp-Ala;13433028;OC(=O)C(C)NC(=O)C(N)CC(=O)O;OC(=O)C(C)NC(=O)C(N)CC(=O)O;1.0;;0.5;100uM;IC50=0.33mM;Glycylsarcosine;Caco-2;"inhibition of Gly-Sar uptake (D-Asp-Ala, L-Asp-Ala); inhibition of Gly-Sar uptake (10mkM)";" Taub, M. E. et al, Int. J. Pharm. (1997) 156, 219-228; A.Biegel et al, J Med Chem(2005),48(13), 4410-9";;PEPT1;1
5171;Human;Asp-Gly;3790510;NC(CC(O)=O)C(NCC(O)=O)=O;NC(CC(O)=O)C(NCC(O)=O)=O;1.0;EC50=0.44mM;0.0;100uM;"IC50=0.91mM; IC50=0.81mM";"Glycylsarcosine; Glycylsarcosine";"Caco-2; MDCK-PEPT1";"inhibition of Gly-Sar uptake; inhibition of Gly-Sar uptake (10mkM); efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM)";" Taub, M. E. et al, Int. J. Pharm. (1997) 156, 219-228; B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44";;PEPT1;1
5172;Human;Asp-Lys;5891510;NC(CC(O)=O)C(NC(CCCCN)C(O)=O)=O;NC(CC(O)=O)C(NC(CCCCN)C(O)=O)=O;1.0;def.;0.5;100uM;"Ki=108mkM; Ki=860mkM";"Glycylsarcosine; Glycylsarcosine";PEPT1-expressing HeLa cell ;"inhibition of Gly-Sar uptake; inhibition of Gly-Sar uptake (10mkM)";"S. Ramamoorthy, Biochim Biophys Acta (1995) 1240, 1-4; A.Biegel et al, J Med Chem(2005),48(13), 4410-9";;PEPT1;1
5173;Human;Asp-Sar;219873322;NC(CC(O)=O)C(N(C)CC(O)=O)=O;NC(CC(O)=O)C(N(C)CC(O)=O)=O;1.0;;0.5;100uM;IC50=0.49mM;Glycylsarcosine;Caco-2;inhibition of Gly-Sar uptake; Taub, M. E. et al, Int. J. Pharm. (1997) 156, 219-228;;PEPT1;1
5175;Human;Bestatin;58970766;O=C(O)C(NC(=O)C(O)C(N)Cc1ccccc1)CC(C)C;O=C(O)C(NC(=O)C(O)C(N)CC1=CC=CC=C1)CC(C)C;1.0;Km=0.34mM;0.5;100uM;Ki=0.4mM;Glycylsarcosine;Caco-2;transport inhibition (Gly-Sar 10mkM);"Y.Sai, A.Tsji. Drug Discovery Today (2004), 9(16), 712-20; P.M.Bahadduri et al, Methods Mol Biol (2010) 637, 65-103; H.Saito, K.Inui. Am J Physiol (1993), 265(2 Pt1), G289-G294; S.Gebauer et al, J Med Chem (2003), 46(26), 5725-34";;PEPT1;1
5176;Human;beta-Asp-Ala;13110253;OC(=O)C(C)NC(=O)CC(N)C(=O)O;OC(=O)C(C)NC(=O)CC(N)C(=O)O;1.0;;0.5;100uM;IC50=0.33mM;Glycylsarcosine;Caco-2;inhibition of Gly-Sar uptake; Taub, M. E. et al, Int. J. Pharm. (1997) 156, 219-228;;PEPT1;1
5177;Human;Captopril;62571862;O=C(O)[C@H]1N(C(=O)[C@H](C)CS)CCC1;O=C(O)[C@@H]1CCCN1C(=O)[C@H](C)CS;1.0; + (review)[Zhang];0.0;100uM;"76% at 0.1mM and 62% at 1mM; Ki=8.7-15.2mM";"Sulpiride; D-Phe-L-Gln";"Caco-2; Xenopus laevis oocyte (rat transporter)";"trans-stimulation and inhibition of Sulpiride uptake (Sulpiride: 100 mkM, Captopril: 1000 mkM); inhibition of D-Phe-L-Gln uptake (rat)";"K. Watanabe, Biol Pharm Bull (2002) 25, 885-90; C. S. Temple, Biochim Biophys Acta (1998) 1373, 277-81; L.Zhang et al, Mol. Pharm (2006), 3(1) 62-69";;PEPT1;1
5178;Human;Carnosine;305840;O=C(O)C(NC(=O)CCN)Cc1cncn1;O=C(O)C(NC(=O)CCN)CC1NC=NC=1;1.0;+ ;0.5;100uM;7% at 10mM ;Formyl-Met-Leu-Phe;Caco-2 ;inhibition of fMLP uptake (fMLP: 0.1 mkM, Carnosine: 10000 mkM) ;"D. Merlin, J Clin Invest (1998) 102, 2011-8; Tsuji A, Drug Metabol Pharmacokin (2002) 17, 253-74 ";;PEPT1;1
5179;Human;Cefaclor;53994733;O=C2N1C(=C(Cl)CS[C@@H]1[C@@H]2NC(=O)[C@@H](c3ccccc3)N)C(=O)O.O;O=C1[C@H]([C@H]2SCC(=C(N12)C(=O)O)[Cl])NC(=O)[C@@H](C3=CC=CC=C3)N;1.0; + (low affinity substrate)[Li];0.0;100uM;"IC50=8.2mM; Ki=>10mM (Ki=~11mM)";Glycylsarcosine;"PEPT1-expressing CHO cell; Caco-2; MDCK-PEPT1";"inhibition of Gly-Sar uptake (Gly-Sar: 20 mkM); transport";"H. K. Han, J Pharm Sci (1999) 88, 347-50; P. Luckner, Eur J Pharm Biopharm (2005) 59, 17-24; M.Li et al, Drug Metab Dispos (2006), 34(4), 547-555";;PEPT1;1
5180;Human;Cefadroxil;337376155;O=C2N1C(=C(CSC1C2NC(=O)C(c3ccc(O)cc3)N)C)C(=O)O;O=C1C(C2SCC(=C(N12)C(=O)O)C)NC(=O)C(C3=CC=C(C=C3)O)N;1.0;+ ;0.0;100uM;"Ki=7.2mM; Ki=9.1mM; Ki=1.45mM; IC50=5.4mM; IC50=0.87mM; 27% at 10mM";"Glycylsarcosine; Valacyclovir; Cefixime; Glycylsarcosine; Glycylsarcosine; Glycylsarcosine";"Caco-2 cell; Xenopus laevis oocyte; PEPT1-expressing CHO cell; PEPT1-expressing HeLa cell";inhibition of Gly-Sar uptake (pH6.0) ;"P. Luckner, Eur J Pharm Biopharm (2005) 59, 17-24; Tsuji A, Drug Metabol Pharmacokin (2002) 17, 253-74; A. Guo, J Pharmacol Exp Ther (1999) 289, 448-54; U. Wenzel, J Pharmacol Exp Ther (1996) 277, 831-9; M. E. Ganapathy, J Biol Chem (1995) 270, 25672-7; R. Liang, J Biol Chem (1995) 270, 6456-63; I.Knuetter et al, Drug Metab Dispos (2009), 37(1), 143-149";;PEPT1;1
5182;Human;Cefdinir;91832405;O=C2N1C(=C(C=C)CS[C@@H]1[C@@H]2NC(=O)C(=NO)c3nc(sc3)N)C(=O)O;O=C1[C@H]([C@H]2SCC(=C(N12)C(=O)O)C=C)NC(=O)C(=NO)C3=CSC(=N3)N;1.0;+ ;0.0;100uM;69% at 10mM ;Glycylsarcosine;PEPT1-expressing HeLa cell ;inhibition of Gly-Sar uptake (Gly-Sar: 20 mkM, Cefdinir: 10000 mkM) ;"M. E. Ganapathy, Biochim Biophys Acta (1997) 1324, 296-308; Tsuji A, Drug Metabol Pharmacokin (2002) 17, 253-74 ";;PEPT1;1
5183;Human;Cefepime;88040237;O=C2N1C(=C(CS[C@@H]1[C@@H]2NC(=O)C(=NOC)c3nc(sc3)N)C[N+]4(C)CCCC4)C([O-])=O;O=C1[C@H]([C@H]2SCC(=C(N12)C(O)=O)C[N+]3(CCCC3)C)NC(=O)C(=NOC)C4=CSC(=N4)N;0.0; - [Bretscneider];0.0;100uM;" - ; Ki =>30mM (Ki=~70mM)";Glycylsarcosine;"PEPT1-expressing HeLa cell; Caco-2";inhibition of Gly-Sar uptake (Gly-Sar: 50 mkM, Cefepime: 2500mkM) ;"M. E. Ganapathy, J Biol Chem (2000) 275, 1699-707; P. Luckner, Eur J Pharm Biopharm (2005) 59, 17-24; B.Bretschneider et al, Pharm Res (1999) 16, 55-61";;PEPT1;0
5184;Human;Cefixime;79350371;O=C2N1C(=C(C=C)CS[C@@H]1[C@@H]2NC(=O)C(=NOCC(=O)O)c3nc(sc3)N)C(=O)O;O=C1[C@H]([C@H]2SCC(=C(N12)C(=O)O)C=C)NC(=O)C(=NOCC(=O)O)C3=CSC(=N3)N;1.0;+ ;0.0;100uM;"Ki=12mM; IC50=10mM; Ki=1.31mM";"Glycylsarcosine; Glycylsarcosine; Cefadroxil";"Caco-2; Xenopus laevis oocyte";inhibition of Gly-Sar uptake (pH6.0) ;"P. Luckner, Eur J Pharm Biopharm (2005) 59, 17-24; M. E. Ganapathy, Biochim Biophys Acta (1997) 1324, 296-308; U. Wenzel, J Pharmacol Exp Ther (1996) 277, 831-9; Tsuji A, Drug Metabol Pharmacokin (2002) 17, 253-74";;PEPT1;1
5186;Human;Cefmetazole;56796204;O=C2N1C(=C(CS[C@@H]1[C@]2(OC)NC(=O)CSCC#N)CSc3nnnn3C)C(=O)O;O=C1[C@]([C@H]2SCC(=C(N12)C(=O)O)CSC3N(N=NN=3)C)(OC)NC(=O)CSCC#N;0.0; - [Bretscneider];0.0;100uM;Ki=28mM ;Glycylsarcosine;Caco-2 ;inhibition of Gly-Sar uptake (pH6.0) ;"P. Luckner, Eur J Pharm Biopharm (2005) 59, 17-24; B.Bretschneider et al, Pharm Res (1999) 16, 55-61";;PEPT1;0
5187;Human;Cefodizime;69739168;O=C2N1C(=C(CS[C@@H]1[C@@H]2NC(=O)/C(=N\OC)c3nc(sc3)N)CSc4nc(c(s4)CC(=O)O)C)C(=O)O;O=C2N1C(=C(CS[C@@H]1[C@@H]2NC(=O)/C(=N\OC)c3nc(sc3)N)CSc4nc(c(s4)CC(=O)O)C)C(=O)O;0.0; - [Bretscneider];0.0;100uM;Ki=22mM ;Glycylsarcosine;Caco-2 ;inhibition of Gly-Sar uptake (pH6.0) ;"P. Luckner, Eur J Pharm Biopharm (2005) 59, 17-24; B.Bretschneider et al, Pharm Res (1999) 16, 55-61; A.Biegel et al, J Med Chem(2005),48(13), 4410-9";;PEPT1;0
5189;Human;Cefotaxime;63527526;O=C2N1C(=C(CS[C@@H]1[C@@H]2NC(=O)C(=NOC)c3nc(sc3)N)COC(=O)C)C(=O)O;O=C1[C@H]([C@H]2SCC(=C(N12)C(=O)O)COC(=O)C)NC(=O)C(=NOC)C3=CSC(=N3)N;0.0; - [Bretscneider];0.0;100uM;Ki=>30mM (Ki=~50mM);Glycylsarcosine;Caco-2 ;inhibition of Gly-Sar uptake (pH6.0) ;"P. Luckner, Eur J Pharm Biopharm (2005) 59, 17-24; B.Bretschneider et al, Pharm Res (1999) 16, 55-61";;PEPT1;0
5190;Human;Cefpirome;84957299;O=C2N1C(=C(CS[C@@H]1[C@@H]2NC(=O)/C(=N\OC)c3nc(sc3)N)C[n+]4cccc5c4CCC5)C([O-])=O;O=C1[C@H]([C@H]2SCC(=C(N12)C(O)=O)C[N+]3=C4C(=CC=C3)CCC4)NC(=O)/C(=N\OC)C5=CSC(=N5)N;0.0; - [Bretscneider];0.0;100uM;Ki=>30mM (Ki=~45mM);Glycylsarcosine;Caco-2 ;inhibition of Gly-Sar uptake (pH6.0) ;"P. Luckner, Eur J Pharm Biopharm (2005) 59, 17-24; B.Bretschneider et al, Pharm Res (1999) 16, 55-61; A.Biegel et al, J Med Chem(2005),48(13), 4410-9";;PEPT1;0
5191;Human;Cefsulodin;52152939;O=C2N1C(=C(CS[C@@H]1[C@@H]2NC(=O)C(c3ccccc3)S(=O)(=O)O)C[n+]4ccc(C(=O)N)cc4)C([O-])=O;O=C1[C@H]([C@H]2SCC(=C(N12)C(O)=O)C[N+]3=CC=C(C=C3)C(=O)N)NC(=O)C(C4=CC=CC=C4)S(=O)(=O)O;0.0; - [Bretscneider];0.0;100uM;Ki=>30mM (Ki=~150mM);Glycylsarcosine;Caco-2 ;inhibition of Gly-Sar uptake (pH6.0) ;"P. Luckner, Eur J Pharm Biopharm (2005) 59, 17-24; B.Bretschneider et al, Pharm Res (1999) 16, 55-61";;PEPT1;0
5192;Human;Ceftazidime;72558828;O=C2N1C(=C(CS[C@@H]1[C@@H]2NC(=O)C(=NOC(C(=O)O)(C)C)c3nc(sc3)N)C[n+]4ccccc4)C([O-])=O;O=C1[C@H]([C@H]2SCC(=C(N12)C(O)=O)C[N+]3=CC=CC=C3)NC(=O)C(=NOC(C(=O)O)(C)C)C4=CSC(=N4)N;0.0; - [Bretscneider];0.0;100uM;" -; Ki=>10mM (Ki=~40mM)";Glycylsarcosine;"PEPT1-expressing HeLa cell; Caco-2";inhibition of Gly-Sar uptake (Gly-Sar: 50 mkM, Ceftatizime: 2500mkM) ;"M. E. Ganapathy, J Biol Chem (2000) 275, 1699-707; P. Luckner, Eur J Pharm Biopharm (2005) 59, 17-24; B.Bretschneider et al, Pharm Res (1999) 16, 55-61";;PEPT1;0
5193;Human;Ceftibuten;97519396;O=C2N1C(=CCS[C@@H]1[C@@H]2NC(=O)C(=CCC(=O)O)c3nc(sc3)N)C(=O)O;O=C1[C@H]([C@H]2SCC=C(N12)C(=O)O)NC(=O)C(=CCC(=O)O)C3=CSC(=N3)N;1.0; +;0.0;100uM;"Ki=340mkM; Ki=870mkM; Ki=710mkM";Glycylsarcosine;"Caco-2 cell; Caco-2; PEPT1-expressing HeLa cell; Xenopus laevis oocyte";inhibition of Gly-Sar uptake (pH6.0) ;"B.Bretschneider et al, Pharm Res (1999) 16, 55-61; P. Luckner, Eur J Pharm Biopharm (2005) 59, 17-24; M. E. Ganapathy, Biochim Biophys Acta (1997) 1324, 296-308; Tsuji A, Drug Metabol Pharmacokin (2002) 17, 253-74";;PEPT1;1
5194;Human;Ceftizoxime;68401810;O=C2N1C(=CCS[C@@H]1[C@@H]2NC(=O)C(=NOC)c3nc(sc3)N)C(=O)O;O=C1[C@H]([C@H]2SCC=C(N12)C(=O)O)NC(=O)C(=NOC)C3=CSC(=N3)N;0.0;- ;;100uM;;;Xenopus laevis oocyte ;uptake ;Tsuji A, Drug Metabol Pharmacokin (2002) 17, 253-74 ;;PEPT1;0
5195;Human;Ceftriaxone;73384595;O=C2N1C(=C(CS[C@@H]1[C@@H]2NC(=O)C(=NOC)c3nc(sc3)N)CSC4=NC(=O)C(=O)NN4C)C(=O)O;O=C1[C@H]([C@H]2SCC(=C(N12)C(=O)O)CSC3N(NC(C(N=3)=O)=O)C)NC(=O)C(=NOC)C4=CSC(=N4)N;0.0; - [Bretscneider];0.0;100uM;Ki=>30mM (Ki=~40mM);Glycylsarcosine;Caco-2 ;inhibition of Gly-Sar uptake (pH6.0) ;"P. Luckner, Eur J Pharm Biopharm (2005) 59, 17-24; B.Bretschneider et al, Pharm Res (1999) 16, 55-61";;PEPT1;0
5196;Human;Cefuroxime;55268752;O=C2N1C(=C(CS[C@@H]1[C@@H]2NC(=O)C(=NOC)c3occc3)COC(=O)N)C(=O)O;O=C1[C@H]([C@H]2SCC(=C(N12)C(=O)O)COC(=O)N)NC(=O)C(=NOC)C3=CC=CO3;0.0; - [Bretscneider];0.0;100uM;Ki=26mM ;Glycylsarcosine;Caco-2 ;inhibition of Gly-Sar uptake (pH6.0) ;"P. Luckner, Eur J Pharm Biopharm (2005) 59, 17-24; B.Bretschneider et al, Pharm Res (1999) 16, 55-61";;PEPT1;0
5197;Human;Cefuxoxime-axetil;64544076;O=C2N1C(=C(CS[C@@H]1[C@@H]2NC(=O)C(=NOC)c3occc3)COC(=O)N)C(=O)OC(OC(=O)C)C;O=C1[C@H]([C@H]2SCC(=C(N12)C(=O)OC(OC(=O)C)C)COC(=O)N)NC(=O)C(=NOC)C3=CC=CO3;1.0; + [Bretschneider];0.0;100uM;Ki=~12mM;Glycylsarcosine;Caco-2 ;inhibition of Gly-Sar uptake (pH6.0) ;P. Luckner, Eur J Pharm Biopharm (2005) 59, 17-24 ;;PEPT1;1
5198;Human;Cephalexin;105879423;O=C2N1C(=C(CS[C@@H]1[C@@H]2NC(=O)[C@@H](c3ccccc3)N)C)C(=O)O;O=C1[C@H]([C@H]2SCC(=C(N12)C(=O)O)C)NC(=O)[C@@H](C3=CC=CC=C3)N;1.0;Km=7.97mkM;0.0;100uM;"Ki=14.4mM; 50% at 10mM; ~50% at 10mM; IC50=5.2mM; IC50=13.7mM; 11% at 10mM";"Glycylsarcosine; Valacyclovir; Cefadroxil; Glycylsarcosine; Glycylsarcosine; Glycylsarcosine";"Caco-2; PEPT1-expressing CHO cell; PEPT1-expressing HeLa cell; Caco-2";inhibition of Gly-Sar uptake (pH6.0) ;"P. Luckner, Eur J Pharm Biopharm (2005) 59, 17-24; H. K. Han, J Pharm Sci (1999) 88, 347-50 ; A. Guo, J Pharmacol Exp Ther (1999) 289, 448-54; K. M. Covitz, Pharm Res (1996) 13, 1631-4; U. Wenzel, J Pharmacol Exp Ther (1996) 277, 831-9; R. Liang, J Biol Chem (1995) 270, 6456-63; K.Watanabe et al, Biol Pharm Bull (2004), 27(4), 559-563";;PEPT1;1
5199;Human;Cephaloridine;50599;O=C2N1C(=C(CS[C@@H]1[C@@H]2NC(=O)Cc3sccc3)C[n+]4ccccc4)C([O-])=O;O=C1[C@H]([C@H]2SCC(=C(N12)C(O)=O)C[N+]3=CC=CC=C3)NC(=O)CC4=CC=CS4;0.0; - [Bretscneider];0.0;100uM;Ki=>30mM ( - at 2.5mM) (Ki=~100mM);Glycylsarcosine;"Caco-2; PEPT1-expressing HeLa cell";"inhibition of Gly-Sar uptake (pH6.0); inhibition of Gly-Sar uptake (Gly-Sar: 50 mkM, CER: 2500mkM)";"P. Luckner, Eur J Pharm Biopharm (2005) 59, 17-24; M. E. Ganapathy, J Biol Chem (2000) 275, 1699-707; B.Bretschneider et al, Pharm Res (1999) 16, 55-61";;PEPT1;0
5201;Human;Cephapirin;21593237;O=C2N1C(=C(CS[C@@H]1[C@@H]2NC(=O)CSc3ccncc3)COC(=O)C)C(=O)O;O=C1[C@H]([C@H]2SCC(=C(N12)C(=O)O)COC(=O)C)NC(=O)CSC3=CC=NC=C3;0.0; - [Bretscneider];0.0;100uM;Ki=>10mM (Ki=~20mM);Glycylsarcosine;Caco-2 ;inhibition of Gly-Sar uptake (pH6.0) ;"P. Luckner, Eur J Pharm Biopharm (2005) 59, 17-24; B.Bretschneider et al, Pharm Res (1999) 16, 55-61";;PEPT1;0
5202;Human;Cephradine;31828509;O=C2N1C(=C(CS[C@@H]1[C@@H]2NC(=O)[C@@H](C3=CCC=CC3)N)C)C(=O)O;O=C1[C@H]([C@H]2SCC(=C(N12)C(=O)O)C)NC(=O)[C@@H](C3CC=CCC=3)N;1.0;+ ;0.0;100uM;"IC50=15.3mM; Ki=9.8mM";"Glycylsarcosine; Glycylsarcosine";"PEPT1-expressing CHO cell; Caco-2";"inhibition of Gly-Sar uptake (Gly-Sar: 20 mkM); inhibition of Gly-Sar uptake (pH6.0)";"H. K. Han, J Pharm Sci (1999) 88, 347-50; P. Luckner, Eur J Pharm Biopharm (2005) 59, 17-24";;PEPT1;1
5204;Human;Cyclacillin;3485141;O=C(O)[C@@H]2N3C(=O)[C@@H](NC(=O)C1(N)CCCCC1)[C@H]3SC2(C)C;O=C(O)[C@H]1C(S[C@@H]2[C@@H](C(N12)=O)NC(=O)C3(CCCCC3)N)(C)C;1.0; +;0.5;100uM;"IC50=350mkM; IC50=600mkM; Ki=500mkM";"Glycylsarcosine; Glycylsarcosine; Glycylsarcosine";"PEPT1-expressing HeLa cell; Caco-2; Caco-2";"inhibition of Gly-Sar uptake (Gly-Sar: 25 mkM); transport inhibition (Gly-Sar 10mkM)";"B.Bretschneider et al, Pharm Res (1999) 16, 55-61; M. E. Ganapathy, J Biol Chem (1995) 270, 25672-7; P. Luckner, Eur J Pharm Biopharm (2005) 59, 17-24; A.Biegel et al, J Med Chem(2005),48(13), 4410-9";;PEPT1;1
5205;Human;Cyclo(Gly-Phe);10125072;O=C(NC1CC2=CC=CC=C2)CNC1=O;O=C1NC(C(NC1)=O)CC2=CC=CC=C2;1.0;Km=90.9mkM ;;100uM;;;Caco-2 ;uptake ;T. Mizuma, J Pharm Pharmacol (2002) 54, 1293-6 ;;PEPT1;1
5206;Human;Cyclo(Gly-Tyr);5845669;O=C(NC1CC2=CC=C(O)C=C2)CNC1=O;O=C1NC(C(NC1)=O)CC2=CC=C(C=C2)O;1.0;Km=62.9mkM ;;100uM;;;Caco-2 ;uptake ;T. Mizuma, J Pharm Pharmacol (2002) 54, 1293-6 ;;PEPT1;1
5207;Human;Cyclo(Phe-Ser);35591005;O=C(NC1CC2=CC=CC=C2)C(CO)NC1=O;O=C1NC(C(NC1CO)=O)CC2=CC=CC=C2;1.0;Km=118mkM ;;100uM;;;Caco-2 ;uptake ;T. Mizuma, J Pharm Pharmacol (2002) 54, 1293-6 ;;PEPT1;1
5208;Human;Cyclo(Ser-Tyr);21754314;O=C(NC1CC2=CC=C(O)C=C2)C(CO)NC1=O;O=C1NC(C(NC1CO)=O)CC2=CC=C(C=C2)O;1.0;Km=21.9mkM ;;100uM;;;Caco-2 ;uptake ;T. Mizuma, J Pharm Pharmacol (2002) 54, 1293-6 ;;PEPT1;1
5209;Human;D-Asp(OBzl)-Ala;188936007;OC(=O)C(C)NC(=O)C(N)CC(=O)OCc1ccccc1;OC(=O)C(C)NC(=O)C(N)CC(=O)OCC1=CC=CC=C1;1.0;;0.5;100uM;"IC50=2.62mM; Ki=90mkM";"Glycylsarcosine; Glycylsarcosine";Caco-2;"inhibition of Gly-Sar uptake (0.5mkCi); inhibition of Gly-Sar uptake (10mkM)";" Taub, M. E. et al, Int. J. Pharm. (1997) 156, 219-228; A.Biegel et al, J Med Chem(2005),48(13), 4410-9";;PEPT1;1
5211;Human;D-Phe-L-Gln;188543784;N[C@H](CC1=CC=CC=C1)C(N[C@@H](CCC(N)=O)C(O)=O)=O;N[C@H](CC1=CC=CC=C1)C(N[C@@H](CCC(N)=O)C(O)=O)=O;1.0;0.4-0.6mM;;100uM;;;Xenopus laevis oocyte ; inhibition of D-Phe-L-Gln ;" Meredith, D et al, J.Physiol. (1998) 512, 629-634; C. S. Temple, Biochim Biophys Acta (1998) 1373, 277-81";;PEPT1;1
5212;Human;Enalapril;75847733;O=C(O)[C@H]2N(C(=O)[C@@H](N[C@H](C(=O)OCC)CCc1ccccc1)C)CCC2;O=C(O)[C@@H]1CCCN1C(=O)[C@@H](N[C@H](C(=O)OCC)CCC2=CC=CC=C2)C;1.0;Km=262mkM;0.0;100uM;"IC50=4.5mM; Ki=4.3-6.5mM";"Glycylsarcosine; D-Phe-L-Gln";"PEPT1-expressing CHO cell; MDCKII-PEPT1";"inhibition of Gly-Sar uptake (Gly-Sar: 20 mkM); inhibition of D-Phe-L-Gln uptake (rat)";"H. K. Han, J Pharm Sci (1999) 88, 347-50; Tsuji A, Drug Metabol Pharmacokin (2002) 17, 253-74; C. S. Temple, Biochim Biophys Acta (1998) 1373, 277-81; L.Liu et al, J Pharmacol Exp Ther (2006) 318(1), 395-402";;PEPT1;1
5213;Human;Enalaprilat;76420729;O=C(O)[C@H]2N(C(=O)[C@@H](N[C@H](C(=O)O)CCc1ccccc1)C)CCC2;O=C(O)[C@@H]1CCCN1C(=O)[C@@H](N[C@H](C(=O)O)CCC2=CC=CC=C2)C;1.0;+ ;;100uM;;;Xenopus laevis oocyte ;uptake ;Tsuji A, Drug Metabol Pharmacokin (2002) 17, 253-74 ;;PEPT1;1
5214;Human;Faropenem;122547493;O=C2N1C(=C(S[C@@H]1[C@H]2[C@H](O)C)[C@@H]3OCCC3)C(=O)O;O=C1[C@@H]([C@H]2SC(=C(N12)C(=O)O)[C@H]3CCCO3)[C@H](O)C;0.0;- ;;100uM;;;Xenopus laevis oocyte ;uptake ;Tsuji A, Drug Metabol Pharmacokin (2002) 17, 253-74 ;;PEPT1;0
5215;Human;FK-089;86070748;O=C2N1C(=CCS[C@@H]1[C@@H]2NC(=O)C(=NOCC(=O)O)c3ncsc3)C(=O)O;O=C1[C@H]([C@H]2SCC=C(N12)C(=O)O)NC(=O)C(=NOCC(=O)O)C3=CSC=N3;1.0;+ ;;100uM;;;Xenopus laevis oocyte ;uptake ;Tsuji A, Drug Metabol Pharmacokin (2002) 17, 253-74 ;;PEPT1;1
5216;Human;Formyl-Met-Leu-Phe (fMLP);59880976;O=CN[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)O)Cc1ccccc1)CC(C)C)CCSC;O=CN[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)O)CC1=CC=CC=C1)CC(C)C)CCSC;1.0;+ ;0.5;100uM;12% at 1mM ;Glycylsarcosine;Xenopus laevis oocyte ;inhibition of Gly-Sar uptake (Gly-Sar: 100 mkM, fMLP: 1000 mkM) ;D. Merlin, J Clin Invest (1998) 102, 2011-8 ;;PEPT1;1
5218;Human;Glycyl-L-glutamine;13115714;NCC(N[C@@H](CCC(N)=O)C(O)=O)=O;NCC(N[C@@H](CCC(N)=O)C(O)=O)=O;1.0;def.;;100uM;;;Caco-2 ;upregulation of mRNA and protein ;D. Walker, J Physiol (1998) 507 ( Pt 3), 697-706 ;1;PEPT1;1
5219;Human;Glycylsarcosine;29816011;O=C(N(C)CC(=O)O)CN;O=C(N(C)CC(=O)O)CN;1.0;"Km=510-830mkM; 290-450mkM; 500-3130mkM; 2100mkM; 860mkM; 1100mkM";0.0;100uM;"Ki=12.8mM; 65% at 1mM; IC50=0.7mM";"Valacyclovir; Sulpiride; Glycylsarcosine";"Caco-2; PEPT1-expressing HeLa cell; PEPT1-expressing CHO cell; PEPT1-overexpressing Caco-2; Caco-2";"uptake; inhibition; transport";"H. Motohashi, Pharm Res (2001) 18, 713-7; R. Liang, J Biol Chem (1995) 270, 6456-63; A. Guo, J Pharmacol Exp Ther (1999) 289, 448-54; H. K. Han, Pharm Res (1998) 15, 1382-6; I.Knuetter et al, Drug Metab Dispos (2009), 37(1), 143-149";;PEPT1;1
5220;Human;Gly-Glu;7412784;NCC(NC(CCC(O)=O)C(O)=O)=O;NCC(NC(CCC(O)=O)C(O)=O)=O;1.0;EC50=1.1mM;0.0;100uM;65% at 1mM;Glycylsarcosine;"Caco-2; MDCK-PEPT1";"inhibition of Gly-Sar uptake (100mkM Gly-Sar); efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM)";"Abe, H et al, Bioconjugate Chem. (1999) 10, 24-31; B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44";;PEPT1;1
5221;Human;Ascorbate;50817;OC1=C(O)C(=O)O[C@@H]1[C@@H](O)CO;OC1[C@H](OC(C=1O)=O)[C@@H](O)CO;0.0;(review-based assumed non-substrate);;100uM;;;;(SVCT1/2 substrate)[Said];H.Said. Annu Rev Physiol (2004), 66, 419-46;;PEPT1;0
5222;;Gly-Gly;556503;NCC(NCC(O)=O)=O;NCC(NCC(O)=O)=O;1.0;"Km=0.2mM; EC50=0.48mM";0.5;100uM;"<20% at 10mM; Ki=0.48-1mM";"Valacyclovir; Glycylsarcosine";"PEPT1-expressing CHO cell; Caco-2; MDCK-PEPT1";"inhibition of VACV uptake (VACV: 20 mkM, Gly-Gly: 10000 mkM); inhibition of Gly-Sar uptake (10mkM); efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM)";"A. Guo, J Pharmacol Exp Ther (1999) 289, 448-54; F.Doring et al, J Clin Invest (1998) 15,2761-67; A.Biegel et al, J Med Chem(2005),48(13), 4410-9; B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44";;PEPT1;1
5223;Human;Biotin;58855;O=C1N[C@@H]2[C@@H](SC[C@@H]2N1)CCCCC(=O)O;O=C1N[C@H]2CS[C@H]([C@H]2N1)CCCCC(=O)O;0.0;(review-based assumed non-substrate);;100uM;;;;(SMVT substrate)[Said];H.Said. Annu Rev Physiol (2004), 66, 419-46;;PEPT1;0
5224;;Dehydroascorbate;490835;O=C1C(=O)C(=O)O[C@@H]1[C@@H](O)CO;O=C1[C@H](OC(C1=O)=O)[C@@H](O)CO;0.0;(review-based assumed non-substrate);;100uM;;;;(SVCT1/2 substrate)[Said];H.Said. Annu Rev Physiol (2004), 66, 419-46;;PEPT1;0
5225;;Gly-Gly-Gly;556332;NCC(NCC(NCC(O)=O)=O)=O;NCC(NCC(NCC(O)=O)=O)=O;1.0;EC50=0.58mM;0.0;100uM;"IC50=1.4mM; IC50=1.07mM";"Glycylsarcosine; Glycylsarcosine";"PEPT1-expressing CHO cell; MDCK-PEPT1";"inhibition of Gly-Sar uptake (Gly-Sar: 25000 mkM); efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM)";"K. M. Covitz, Pharm Res (1996) 13, 1631-4; B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44";;PEPT1;1
5226;Human;Lipoate;1077298;O=C(O)CCCCC1SSCC1;O=C(O)CCCCC1CCSS1;0.0;(review-based assumed non-substrate);;100uM;;;;(SMVT substrate)[Said];H.Said. Annu Rev Physiol (2004), 66, 419-46;;PEPT1;0
5227;;Gly-Gly-Ile;69242406;NCC(NCC(NC([C@@H](CC)C)C(O)=O)=O)=O;NCC(NCC(NC([C@@H](CC)C)C(O)=O)=O)=O;1.0;def.;0.5;100uM;10% at 10mM;Glycylsarcosine;PEPT1-expressing HeLa cell ;inhibition of Gly-Sar uptake (Gly-Sar: 20 mkM, Gly-Gly-Ile: 10000 mkM) ;R. Liang, J Biol Chem (1995) 270, 6456-63 ;;PEPT1;1
5228;Human;Pantothenate;79834;O=C(NCCC(=O)O)[C@H](O)C(C)(C)CO;O=C(NCCC(=O)O)[C@H](O)C(C)(C)CO;0.0;(review-based assumed non-substrate);;100uM;;;;(SMVT substrate)[Said];H.Said. Annu Rev Physiol (2004), 66, 419-46;;PEPT1;0
5229;;Gly-Gly-Pro;14379761;NCC(NCC(N1C(C(O)=O)CCC1)=O)=O;NCC(NCC(N1CCCC1C(O)=O)=O)=O;1.0;def.;0.5;100uM;13% at 10mM;Glycylsarcosine;PEPT1-expressing HeLa cell ;inhibition of Gly-Sar uptake (Gly-Sar: 20 mkM, Gly-Gly-Pro: 10000 mkM) ;R. Liang, J Biol Chem (1995) 270, 6456-63 ;;PEPT1;1
5230;Human;Gly-Leu;688142;NCC(NC(CC(C)C)C(O)=O)=O;NCC(NC(CC(C)C)C(O)=O)=O;1.0;EC50=0.17mM;1.0;100uM;"7% at 10mM; <20% at 10mM; 20% at 1mM; IC50=70mkM; Ki=160mkM";"Formyl-Met-Leu-Phe; Valacyclovir; Glycylsarcosine; Glycylsarcosine; Glycylsarcosine";"Caco-2; PEPT1-expressing CHO cell; MDCK-PEPT1; Caco-2";"inhibition of fMLP uptake (fMLP: 0.1 mkM, Gly-Leu: 10000 mkM); inhibition of VACV uptake (VACV: 20 mkM, Gly-Leu: 10000 mkM); efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM); transport inhibition (Gly-Sar 10mkM)";"D. Merlin, J Clin Invest (1998) 102, 2011-8; A. Guo, J Pharmacol Exp Ther (1999) 289, 448-54; Abe, H et al, Bioconjugate Chem. (1999) 10, 24-31; B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44; S.Gebauer et al, J Med Chem (2003), 46(26), 5725-34";;PEPT1;1
5231;Human;Thiamine;59438;[Cl-].n1c(c(cnc1C)C[n+]2c(c(sc2)CCO)C)N;N1C(=NC=C(C=1N)C[N+]2=CSC(=C2C)CCO)C;0.0;(review-based assumed non-substrate);;100uM;;;;(SLC19A2/3 substrate);H.Said. Annu Rev Physiol (2004), 66, 419-46;;PEPT1;0
5232;;Gly-Phe;721664;NCC(NC(CC1=CC=CC=C1)C(O)=O)=O;NCC(NC(CC1=CC=CC=C1)C(O)=O)=O;1.0;EC50=0.13mM;0.5;100uM;"20% at 1mM; IC50=0.17mM";"Glycylsarcosine; Glycylsarcosine";"Caco-2; MDCK-PEPT1";"inhibition of Gly-Sar uptake (100mkM Gly-Sar); efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM)";"Abe, H et al, Bioconjugate Chem. (1999) 10, 24-31; B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44; B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44";;PEPT1;1
5233;Human;Gly-Pro;704154;NCC(N1C(C(O)=O)CCC1)=O;NCC(N1CCCC1C(O)=O)=O;1.0;EC50=0.13mM;0.5;100uM;"7% at 10mM; 22% at 10mM; 30% at 1mM; Ki=160mkM; Ki=0.13-0.33mM";"Glycylsarcosine; Formyl-Met-Leu-Phe; Glycylsarcosine; Glycylsarcosine; Glycylsarcosine";"PEPT1-expressing HeLa cell; Caco-2 ; Caco-2; Caco-2; MDCK-PEPT1";"inhibition of Gly-Sar uptake (Gly-Sar: 20 mkM, Gly-Pro: 10000 mkM); inhibition of fMLP uptake (fMLP: 0.1 mkM, Gly-Pro: 10000 mkM); inhibition of Gly-Sar uptake (10mkM); efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM)";"R. Liang, J Biol Chem (1995) 270, 6456-63; D. Merlin, J Clin Invest (1998) 102, 2011-8; Abe, H et al, Bioconjugate Chem. (1999) 10, 24-31; M.Brandsch et al, Eur J Biochem (1999), 266(2), 502-508; A.Biegel et al, J Med Chem(2005),48(13), 4410-9; B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44";;PEPT1;1
5234;Human;Leu-Leu;2883365;NC(CC(C)C)C(NC(CC(C)C)C(O)=O)=O;NC(CC(C)C)C(NC(CC(C)C)C(O)=O)=O;1.0;EC50=80mkM;0.5;100uM;"<20% at 10mM; IC50=0.17mM";"Valacyclovir; Glycylsarcosine";"PEPT1-expressing CHO cell; MDCK-PEPT1";"inhibition of VACV uptake (VACV: 20 mkM, Leu-Leu: 10000 mkM); efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM)";"A. Guo, J Pharmacol Exp Ther (1999) 289, 448-54; B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44";;PEPT1;1
5235;Human;Leu-Pro;6403356;NC(CC(C)C)C(N1C(C(O)=O)CCC1)=O;NC(CC(C)C)C(N1CCCC1C(O)=O)=O;1.0;def.;0.8;100uM;"8% at 10mM; Ki=0.18mM; Ki=0.11mM";"Glycylsarcosine; Glycylsarcosine; Glycylsarcosine";"PEPT1-expressing HeLa cell; Caco-2; Caco-2";"inhibition of Gly-Sar uptake (Gly-Sar: 20 mkM, Leu-Pro: 10000 mkM); inhibition of Gly-Sar uptake (10mkM); inhibition of Gly-Sar uptake (10mkM)";"R. Liang, J Biol Chem (1995) 270, 6456-63; A.Biegel et al, J Med Chem(2005),48(13), 4410-9; S.Gebauer et al, J Med Chem (2003), 46(26), 5725-34";;PEPT1;1
5236;Human;Levodopa;59927;O=C(O)[C@@H](N)Cc1cc(O)c(O)cc1;O=C(O)[C@@H](N)CC1=CC=C(C(=C1)O)O;0.0;def. (aminoacid transporter substrate);0.0;100uM;IC50=141.2mM ;Glycylsarcosine;PEPT1-expressing CHO cell ;inhibition of Gly-Sar uptake (Gly-Sar: 20 mkM) ;"A.Tsuji, I.Tamai, Pharm Res (1996) 13, 963-977; H. K. Han, J Pharm Sci (1999) 88, 347-50";;PEPT1;0
5237;Human;Levodopa-L-Phe;95316033;OC(C(CC1=CC=CC=C1)NC([C@H](Cc2ccc(O)c(O)c2)N)=O)=O;OC(C(CC1=CC=CC=C1)NC([C@H](CC2=CC(=C(C=C2)O)O)N)=O)=O;1.0;+ ;0.0;100uM;~20% at 1mM;Glycylsarcosine;"Caco-2; Xenopus laevis oocyte";"inhibition of Gly-Sar uptake (Gly-Sar: 20 mkM, L-dopa-L-Phe: 1000 mkM); uptake";I. Tamai, J Pharm Sci (1998) 87, 1542-6 ;;PEPT1;1
5241;Human;L-Glu[acyclovir]-Sar;610254085;OC(CN(C(C(CCC(OCCOCn1cnc2c1NC(N)=NC2=O)=O)N)=O)C)=O;OC(CN(C(C(CCC(OCCOCN1C2=C(N=C1)C(N=C(N2)N)=O)=O)N)=O)C)=O;0.0; - [Thomsen] (binds, but not transported);0.5;100uM;Ki=280mkM;Glycylsarcosine;Caco-2 ;inhibition of Gly-Sar uptake ;"A. E. Thomsen, J Control Release (2003) 86, 279-92; A.E.Thomsen et al, Eur J Pharm Sci. (2004) 23, 319-25";;PEPT1;0
5242;Human;Lisinopril;83915837;O=C(O)[C@H]2N(C(=O)[C@@H](N[C@H](C(=O)O)CCc1ccccc1)CCCCN)CCC2;O=C(O)[C@@H]1CCCN1C(=O)[C@@H](N[C@H](C(=O)O)CCC2=CC=CC=C2)CCCCN;0.0;- ;0.0;100uM; - at 10mM;cefadroxil;Xenopus laevis oocyte ;uptake ;"Tsuji A, Drug Metabol Pharmacokin (2002) 17, 253-74; A.Tsuji, I.Tamai, Pharm Res (1996) 13, 963-977";;PEPT1;0
5243;Human;Loracarbef;76470661;ClC3=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@@H](c1ccccc1)N)[C@H]2CC3;[Cl]C1CC[C@@H]2[C@@H](C(N2C=1C(=O)O)=O)NC(=O)[C@@H](C3=CC=CC=C3)N;0.8; def.(oral cephalosporin)[Tsuji];0.5;100uM;72.6-60.3% at 10mM;Cefadroxil;Caco-2 ;inhibition of Cefadroxil uptake (apical pH 5.5-6.5, Cefadroxil: 1000 mkM, Loracarbef: 10000 mkM) ;"U. Wenzel, J Pharmacol Exp Ther (1996) 277, 831-9; A.Tsuji, I.Tamai, Pharm Res (1996) 13, 963-977";;PEPT1;1
5244;Human;L-Phe-D-Pro;28426519;NC(CC1=CC=CC=C1)C(N2C(C(O)=O)CCC2)=O;NC(CC1=CC=CC=C1)C(N2CCCC2C(O)=O)=O;1.0;+ ;;100uM;;;Xenopus laevis oocyte ;uptake ;I. Tamai, J Pharm Sci (1998) 87, 1542-6 ;;PEPT1;1
5247;Human;Lys-Ala;17043719;NC(CCCCN)C(NC(C)C(O)=O)=O;NC(CCCCN)C(NC(C)C(O)=O)=O;1.0;def.;0.5;100uM;"Ki=419mkM; Ki=340mkM";"Glycylsarcosine; Glycylsarcosine";"PEPT1-expressing HeLa cell; Caco-2";"inhibition of Gly-Sar uptake; inhibition of Gly-Sar uptake (10mkM)";"S. Ramamoorthy, Biochim Biophys Acta (1995) 1240, 1-4; A.Biegel et al, J Med Chem(2005),48(13), 4410-9";;PEPT1;1
5250;Human;Lys-fluorescein-Sar;756461457;S=C(NCCCCC(C(N(C)CC(O)=O)=O)N)Nc1ccc(C2(c3c(Oc4c2ccc(O)c4)cc(O)cc3)OC5=O)c5c1;S=C(NCCCCC(C(N(C)CC(O)=O)=O)N)NC1=CC5=C(C=C1)C2(C4C(OC3C2=CC=C(C=3)O)=CC(=CC=4)O)OC5=O;0.0;indirect evidence (no saturation);0.5;100uM;<10% at 1mM;Glycylsarcosine;Caco-2;inhibition of Gly-Sar uptake (100mkM Gly-Sar);Abe, H et al, Bioconjugate Chem. (1999) 10, 24-31.;;PEPT1;0
5251;Human;Lys-Pro;52766275;NC(CCCCN)C(N1C(C(O)=O)CCC1)=O;NC(CCCCN)C(N1CCCC1C(O)=O)=O;1.0;EC50=0.19mM;0.5;100uM;"Ki=350mkM; IC50=0.39mM";"Glycylsarcosine; Glycylsarcosine";"Caco-2; MDCK-PEPT1";"inhibition of Gly-Sar uptake; efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM)";"I. Knutter, Biochemistry (2001) 40, 4454-8; B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44";;PEPT1;1
5253;Human;Methyldopa;555306;O=C(O)C(NC)Cc1cc(O)c(O)cc1;O=C(O)C(NC)CC1=CC=C(C(=C1)O)O;0.0;def. (aminoacid transporter substrate);0.0;100uM;IC50=151.6mM ;Glycylsarcosine;PEPT1-expressing CHO cell ;inhibition of Gly-Sar uptake (Gly-Sar: 20 mkM) ;"A.Tsuji, I.Tamai, Pharm Res (1996) 13, 963-977; H. K. Han, J Pharm Sci (1999) 88, 347-50 ";;PEPT1;0
5254;Human;Methyldopa-L-Phe;119933710;O=C(O)[C@@H](NC(=O)[C@@](N)(Cc1cc(O)c(O)cc1)C)Cc2ccccc2;O=C(O)[C@@H](NC(=O)[C@](N)(CC1=CC=C(C(=C1)O)O)C)CC2=CC=CC=C2;1.0; +;;100uM;;;;(review);Y.Sai, A.Tsji. Drug Discovery Today (2004), 9(16) 712-20;;PEPT1;1
5257;Human;Phe-Phe;2577404;NC(CC1=CC=CC=C1)C(NC(CC2=CC=CC=C2)C(O)=O)=O;NC(CC1=CC=CC=C1)C(NC(CC2=CC=CC=C2)C(O)=O)=O;1.0;EC50=30mkM;1.0;100uM;"Ki=110mkM; IC50=80mkM";"Glycylsarcosine; Glycylsarcosine";"Xenopus laevis oocyte; Caco-2; MDCK-PEPT1";"uptake; inhibition of Gly-Sar uptake (10mkM); efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM)";"I. Tamai, J Pharm Sci (1998) 87, 1542-6; A.Biegel et al, J Med Chem(2005),48(13), 4410-9; B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44; S.Gebauer et al, J Med Chem (2003), 46(26), 5725-34";;PEPT1;1
5258;Human;Sulpiride;15676161;O=S(=O)(N)c1cc(c(OC)cc1)C(=O)NCC2N(CC)CCC2;O=S(=O)(N)C1=CC=C(C(=C1)C(=O)NCC2CCCN2CC)OC;1.0;indirect evidence;;100uM;;;Caco-2;trans-stimulation and inhibition of Sulpiride uptake (Sulpiride: 100 mkM);K. Watanabe, Biol Pharm Bull (2002) 25, 885-90;;PEPT1;1
5259;Human;Temocapril;111902579;O=C(OCC)[C@@H](NC1C(=O)N(C[C@H](SC1)c2sccc2)CC(=O)O)CCc3ccccc3;O=C(OCC)[C@@H](NC1CS[C@@H](CN(C1=O)CC(=O)O)C2=CC=CS2)CCC3=CC=CC=C3;1.0;+ ;;100uM;;;Xenopus laevis oocyte ;uptake ;Tsuji A, Drug Metabol Pharmacokin (2002) 17, 253-74 ;;PEPT1;1
5260;Human;Temocaprilat;110221539;O=C(O)[C@@H](N[C@@H]1C(=O)N(C[C@H](SC1)c2sccc2)CC(=O)O)CCc3ccccc3;O=C(O)[C@@H](N[C@H]1CS[C@@H](CN(C1=O)CC(=O)O)C2=CC=CS2)CCC3=CC=CC=C3;1.0;+ ;;100uM;;;Xenopus laevis oocyte ;uptake ;Tsuji A, Drug Metabol Pharmacokin (2002) 17, 253-74 ;;PEPT1;1
5261;Human;Valacyclovir;124832264;O=C(OCCOCn1c2NC(=NC(=O)c2nc1)N)[C@@H](N)C(C)C;O=C(OCCOCN1C=NC2C(N=C(NC1=2)N)=O)[C@@H](N)C(C)C;1.0;"Km=292mkM; Km=2200-7400mkM; Km=1640mkM";0.2;100uM;"Ki=490mkM; Ki=740mkM; IC50=1100mkM; Ki=910mkM";"Glycylsarcosine; Glycylsarcosine; Glycylsarcosine; Cefadroxil";"Caco-2; PEPT1-expressing HeLa cell; PEPT1-expressing CHO cell; Caco-2";"inhibition of Gly-Sar uptake; inhibition of Gly-Sar uptake, L-form (Gly-Sar: 20 mkM); transepithelial transport (apical to basal), L-form; uptake (pH 7.9; 7.5; 6.8; 6.2; 5.5); uptake ";"M. E. Ganapathy, Biochem Biophys Res Commun (1998) 246, 470-5; ;H. Han, Pharm Res (1998) 15, 1154-9; H. Han, Pharm Res (1998) 15, 1154-9; P. Balimane, Biopharm Drug Dispos (2000) 21, 165-74; A. Guo, J Pharmacol; P.M.Bahadduri et al, Methods Mol Biol (2010) 637, 65-103; A.E.Thomsen et al, Eur J Pharm Sci. (2004) 23, 319-25; A.Guo et al, J Pharmacol Exp Ther (1999), 289(1), 448-454.";;PEPT1;1
5262;Human;Val-Lys;22677629;NC(C(C)C)C(NC(CCCCN)C(O)=O)=O;NC(C(C)C)C(NC(CCCCN)C(O)=O)=O;1.0;def.;0.0;100uM;35% at 1mM;Glycylsarcosine;Caco-2;inhibition of Gly-Sar uptake (100mkM Gly-Sar);Abe, H et al, Bioconjugate Chem. (1999) 10, 24-31.;;PEPT1;1
5264;Human;Val-Lys-fluorescein;732232983;S=C(NCCCCC(C(O)=O)NC(C(C(C)C)N)=O)Nc1ccc(C2(c3c(Oc4c2ccc(O)c4)cc(O)cc3)OC5=O)c5c1;S=C(NCCCCC(C(O)=O)NC(C(C(C)C)N)=O)NC1=CC5=C(C=C1)C2(C4C(OC3C2=CC=C(C=3)O)=CC(=CC=4)O)OC5=O;0.1;indirect evidence (no saturation);1.0;100uM;"Ki=5mkM; 36.4% at 0.2mM; 45% at 0.2mM";"Glycylsarcosine; cefadroxil; cephradine";Caco-2;inhibition of Gly-Sar uptake (100mkM Gly-Sar);Abe, H et al, Bioconjugate Chem. (1999) 10, 24-31.;;PEPT1;0
5265;Human;Carfecillin;27025496;O=C(O)[C@@H]3N4C(=O)[C@@H](NC(=O)C(c1ccccc1)C(=O)Oc2ccccc2)[C@H]4SC3(C)C;O=C(O)[C@H]1C(S[C@@H]2[C@@H](C(N12)=O)NC(=O)C(C3=CC=CC=C3)C(=O)OC4=CC=CC=C4)(C)C;0.8; def.(oral cephalosporin)[Tsuji];;100uM;;;;;A.Tsuji, I.Tamai, Pharm Res (1996) 13, 963-977;;PEPT1;1
5266;Human;Cefatrizine;51627146;O=C2N1C(=C(CS[C@@H]1[C@@H]2NC(=O)[C@@H](c3ccc(O)cc3)N)CSc4nnnc4)C(=O)O;O=C1[C@H]([C@H]2SCC(=C(N12)C(=O)O)CSC3C=NNN=3)NC(=O)[C@@H](C4=CC=C(C=C4)O)N;0.8; def.(oral cephalosporin)[Tsuji];;100uM;;;;;A.Tsuji, I.Tamai, Pharm Res (1996) 13, 963-977;;PEPT1;1
5267;Human;S863390;130024929;O=C(N[C@H](C(=O)NC(=O)[C@@H](N[C@@H](CC1CCCCC1)[C@@H](O)CCCc2ncccc2)Cc3cncn3)Cc4ccccc4)CC(C)C;O=C(N[C@H](C(=O)NC(=O)[C@@H](N[C@@H](CC1CCCCC1)[C@@H](O)CCCC2=CC=CC=N2)CC3NC=NC=3)CC4=CC=CC=C4)CC(C)C;0.8;def.(proposed substrate)[Tsuji];;100uM;;;;;A.Tsuji, I.Tamai, Pharm Res (1996) 13, 963-977;;PEPT1;1
5268;Human;pGlu-levodopa-Pro;1060774119;O=C(N1C(C(O)=O)CCC1)C(NC(C2N(C(O)=O)C(CC2)=O)=O)CC3=CC(O)=C(O)C=C3;O=C(N1CCCC1C(O)=O)C(NC(C2CCC(N2C(O)=O)=O)=O)CC3=CC=C(C(=C3)O)O;1.0;;;100uM;;;;;A.Tsuji, I.Tamai, Pharm Res (1996) 13, 963-977;;PEPT1;1
5269;Human;CRC 220;146663958;CC1=CC(OC)=C(C)C(C)=C1S(NC(CC(O)=O)C(NC(CC2=CC=C(C(N)=N)C=C2)C(N3CCCCC3)=O)=O)(=O)=O;CC1=C(C(=C(C(=C1)OC)C)C)S(NC(CC(O)=O)C(NC(CC2=CC=C(C=C2)C(N)=N)C(N3CCCCC3)=O)=O)(=O)=O;0.8;def.(proposed substrate)[Tsuji];;100uM;;;;;A.Tsuji, I.Tamai, Pharm Res (1996) 13, 963-977;;PEPT1;1
5270;Human;Cephaloglycine;3577013;O=C2N1C(=C(CS[C@@H]1[C@@H]2NC(=O)[C@@H](c3ccccc3)N)COC(=O)C)C(=O)O;O=C1[C@H]([C@H]2SCC(=C(N12)C(=O)O)COC(=O)C)NC(=O)[C@@H](C3=CC=CC=C3)N;1.0;def.;0.5;100uM; + at 10mM;cefadroxil;oocytes;;A.Tsuji, I.Tamai, Pharm Res (1996) 13, 963-977;;PEPT1;1
5271;Rabbit;alpha-D-Glucopyranose;492626;O[C@H]1[C@H](O)[C@H](O[C@H](O)[C@@H]1O)CO;O[C@@H]1[C@H]([C@H](O[C@@H]([C@H]1O)CO)O)O;0.0;(review-based assumed non-substrate);;100uM;;;;(glucose transporter substrate);A.Tsuji, I.Tamai, Pharm Res (1996) 13, 963-977;;PEPT1;0
5272;;alpha-Methylaminoisobutyrate;2566349;O=C(O)C(NC)(C)C;O=C(O)C(NC)(C)C;0.0;(review-based assumed non-substrate);;100uM;;;;def. (aminoacid transporter substrate);A.Tsuji, I.Tamai, Pharm Res (1996) 13, 963-977;;PEPT1;0
5273;;Arginine;74793;O=C(O)[C@@H](N)CCCN=C(N)N;O=C(O)[C@@H](N)CCCN=C(N)N;0.0;(review-based assumed non-substrate);;100uM;;;;def. (aminoacid transporter substrate);A.Tsuji, I.Tamai, Pharm Res (1996) 13, 963-977;;PEPT1;0
5274;;Baclofen;1134470;Clc1ccc(cc1)C(CN)CC(=O)O;[Cl]C1=CC=C(C=C1)C(CN)CC(=O)O;0.0;(review-based assumed non-substrate);;100uM;;;;def. (aminoacid transporter substrate);A.Tsuji, I.Tamai, Pharm Res (1996) 13, 963-977;;PEPT1;0
5275;;Benzoate;65850;O=C(O)c1ccccc1;O=C(O)C1=CC=CC=C1;0.0;(review-based assumed non-substrate);;100uM;;;;(monocarobix acid transporter substrate);A.Tsuji, I.Tamai, Pharm Res (1996) 13, 963-977;;PEPT1;0
5276;;beta-Alanine;107959;O=C(O)CCN;O=C(O)CCN;0.0;(review-based assumed non-substrate);;100uM;;;;def. (aminoacid transporter substrate);A.Tsuji, I.Tamai, Pharm Res (1996) 13, 963-977;;PEPT1;0
5277;;Carnitine;541151;O=C(O)CC(O)C[N+](C)(C)C;O=C(O)CC(O)C[N+](C)(C)C;0.0;(review-based assumed non-substrate);;100uM;;;;def. (aminoacid transporter substrate);A.Tsuji, I.Tamai, Pharm Res (1996) 13, 963-977;;PEPT1;0
5278;;D-Cycloserine;68417;O=C1NOC[C@H]1N;O=C1[C@@H](CON1)N;0.0;(review-based assumed non-substrate);;100uM;;;;def. (aminoacid transporter substrate);A.Tsuji, I.Tamai, Pharm Res (1996) 13, 963-977;;PEPT1;0
5279;;Dextrose;50997;O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO;O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO;0.0;(review-based assumed non-substrate);;100uM;;;;(glucose transporter substrate);A.Tsuji, I.Tamai, Pharm Res (1996) 13, 963-977;;PEPT1;0
5280;;D-Fructofuranose;10247468;O[C@H]1[C@H](O)[C@H](OC1(O)CO)CO;O[C@@H]1C(O[C@@H]([C@H]1O)CO)(O)CO;0.0;(review-based assumed non-substrate);;100uM;;;;(glucose transporter substrate);A.Tsuji, I.Tamai, Pharm Res (1996) 13, 963-977;;PEPT1;0
5281;;D-Fructopyranose;6347019;O[C@@H]1C(O)(OC[C@@H](O)[C@H]1O)CO;O[C@H]1[C@@H]([C@@H](COC1(O)CO)O)O;0.0;(review-based assumed non-substrate);;100uM;;;;(glucose transporter substrate);A.Tsuji, I.Tamai, Pharm Res (1996) 13, 963-977;;PEPT1;0
5282;;Foscarnet;4428959;O=C(O)P(=O)(O)O;O=C(O)P(=O)(O)O;0.0;(review-based assumed non-substrate);;100uM;;;;(phosphate transporter substrate);A.Tsuji, I.Tamai, Pharm Res (1996) 13, 963-977;;PEPT1;0
5283;Rabbit;Fosfomycin;23155024;O=P(O)(O)[C@H]1O[C@H]1C;O=P(O)(O)[C@@H]1[C@@H](O1)C;0.0;(review-based assumed non-substrate);;100uM;;;;(phosphate transporter substrate);A.Tsuji, I.Tamai, Pharm Res (1996) 13, 963-977;;PEPT1;0
5284;Rabbit;Fructose;57487;O=C([C@@H](O)[C@H](O)[C@H](O)CO)CO;O=C([C@@H](O)[C@H](O)[C@H](O)CO)CO;0.0;(review-based assumed non-substrate);;100uM;;;;(glucose transporter substrate);A.Tsuji, I.Tamai, Pharm Res (1996) 13, 963-977;;PEPT1;0
5285;;Gabapentin;60142963;O=C(O)CC1(CN)CCCCC1;O=C(O)CC1(CCCCC1)CN;0.0;(review-based assumed non-substrate);;100uM;;;;def. (aminoacid transporter substrate);A.Tsuji, I.Tamai, Pharm Res (1996) 13, 963-977;;PEPT1;0
5286;;Hydroxyproline;51354;O=C(O)[C@H]1NC[C@H](O)C1;O=C(O)[C@@H]1C[C@H](CN1)O;0.0;(review-based assumed non-substrate);;100uM;;;;def. (aminoacid transporter substrate);A.Tsuji, I.Tamai, Pharm Res (1996) 13, 963-977;;PEPT1;0
5287;;L-Alanine;56417;O=C(O)[C@@H](N)C;O=C(O)[C@@H](N)C;0.0;(review-based assumed non-substrate);;100uM;;;;def. (aminoacid transporter substrate);A.Tsuji, I.Tamai, Pharm Res (1996) 13, 963-977;;PEPT1;0
5288;;L-Glutamate;56860;OC(=O)[C@@H](N)CCC(=O)O;OC(=O)[C@@H](N)CCC(=O)O;0.0;(review-based assumed non-substrate);;100uM;;;;def. (aminoacid transporter substrate);A.Tsuji, I.Tamai, Pharm Res (1996) 13, 963-977;;PEPT1;0
5289;;Lysine;56871;O=C(O)[C@@H](N)CCCCN;O=C(O)[C@@H](N)CCCCN;0.0;(review-based assumed non-substrate);;100uM;;;;def. (aminoacid transporter substrate);A.Tsuji, I.Tamai, Pharm Res (1996) 13, 963-977;;PEPT1;0
5290;;Ornithine;70268;O=C(O)[C@@H](N)CCCN;O=C(O)[C@@H](N)CCCN;0.0;(review-based assumed non-substrate);;100uM;;;;def. (aminoacid transporter substrate);A.Tsuji, I.Tamai, Pharm Res (1996) 13, 963-977;;PEPT1;0
5291;;Phenylalanine;63912;O=C(O)[C@@H](N)Cc1ccccc1;O=C(O)[C@@H](N)CC1=CC=CC=C1;0.0;(review-based assumed non-substrate);;100uM;;;;def. (aminoacid transporter substrate);A.Tsuji, I.Tamai, Pharm Res (1996) 13, 963-977;;PEPT1;0
5292;;Pipecolate;535751;N1CCCCC1C(=O)O;N1C(CCCC1)C(=O)O;0.0;(review-based assumed non-substrate);;100uM;;;;def. (aminoacid transporter substrate);A.Tsuji, I.Tamai, Pharm Res (1996) 13, 963-977;;PEPT1;0
5293;;Proline;147853;O=C(O)[C@H]1NCCC1;O=C(O)[C@@H]1CCCN1;0.0;(review-based assumed non-substrate);;100uM;;;;def. (aminoacid transporter substrate);A.Tsuji, I.Tamai, Pharm Res (1996) 13, 963-977;;PEPT1;0
5294;;Taurine;107357;NCCS(=O)(=O)O;NCCS(=O)(=O)O;0.0;(review-based assumed non-substrate);;100uM;;;;def. (aminoacid transporter substrate);A.Tsuji, I.Tamai, Pharm Res (1996) 13, 963-977;;PEPT1;0
5295;;Valganciclovir;175865595;O=C(OCC(OCn1c2NC(=NC(=O)c2nc1)N)CO)[C@@H](N)C(C)C;O=C(OCC(OCN1C=NC2C(N=C(NC1=2)N)=O)CO)[C@@H](N)C(C)C;1.0;(designed substrate);0.0;100uM;Ki=1.68mM;Glycylsarcosine;Caco-2 cell, Xenopus laevis oocytes/PEPT1;transport, inhibition studies;"M.Sugawara et al, J Pharm Sci. (2000) 89, 781-9; P.M.Bahadduri et al, Methods Mol Biol (2010) 637, 65-103";;PEPT1;1
5299;;LY544344;441765986;O=C(O)[C@@H]1[C@H]2[C@](NC(=O)[C@@H](N)C)(C(=O)O)CC[C@@H]12;O=C(O)[C@@H]1[C@H]2[C@](NC(=O)[C@@H](N)C)(C(=O)O)CC[C@@H]12;1.0; +;;100uM;;;; SYN: (1S,2S,5R,6S)-2-[(2S)-(2-amino)propionyl]aminobicyclo[3.1.0.]hexen-2,6-dicarboxylate;"E.J.Perkins and T.Abraham. Drug Metabolism and Disposition (2007) 35:10, 1903-9; P.M.Bahadduri et al, Methods Mol Biol (2010) 637, 65-103";;PEPT1;1
5300;Human;LY354740;176199487;O=C(O)[C@@H]1[C@H]2[C@](N)(C(=O)O)CC[C@@H]12;O=C(O)[C@@H]1[C@H]2[C@](N)(C(=O)O)CC[C@@H]12;0.0; -;;100uM;;;;"SYN: Eglumegad; (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylate";"E.J.Perkins and T.Abraham. Drug Metabolism and Disposition (2007) 35:10, 1903-9; P.M.Bahadduri et al, Methods Mol Biol (2010) 637, 65-103";;PEPT1;0
5301;Human;Acyclovir;59277893;O=C2/N=C(\Nc1n(cnc12)COCCO)N;O=C1C2N=CN(C=2NC(=N1)N)COCCO;0.0; -;;100uM;;;Caco-2;transport;"A.E.Thomsen et al, Eur J Pharm Sci. (2004) 23, 319-25; P.M.Bahadduri et al, Methods Mol Biol (2010) 637, 65-103";;PEPT1;0
5302;Human;Ganciclovir;82410320;O=C2N=C(Nc1n(cnc12)COC(CO)CO)N;O=C1C2N=CN(C=2NC(=N1)N)COC(CO)CO;0.0; -;;100uM;;;Xenopus laevis oocytes/PEPT1;transport;"M.Sugawara et al, J Pharm Sci. (2000) 89, 781-9; P.M.Bahadduri et al, Methods Mol Biol (2010) 637, 65-103";;PEPT1;0
5303;Human;Val-Tyr;3061914;NC(C(C)C)C(NC(CC1=CC=C(O)C=C1)C(O)=O)=O;NC(C(C)C)C(NC(CC1=CC=C(O)C=C1)C(O)=O)=O;1.0; +;1.0;100uM;Ki=0.1mM;Glycylsarcosine;"rat in vivo; Caco-2";"transport in rat; transport inhibition (Gly-Sar 10mkM)";"M.Sato et al, J. Agric. Food Chem (2002) 9, 6245-52; A.Biegel et al, J Med Chem(2005),48(13), 4410-9; S.Gebauer et al, J Med Chem (2003), 46(26), 5725-34";;PEPT1;1
5304;Human;Ile-Tyr;38579214;NC([C@@](CC)([H])C)C(NC(CC1=CC=C(O)C=C1)C(O)=O)=O;NC([C@@](CC)([H])C)C(NC(CC1=CC=CC=C1)C(O)=O)=O;1.0; +;;100uM;;;in vivo;transport;M.Sato et al, J. Agric. Food Chem (2002) 9, 6245-52;;PEPT1;1
5305;Rat;Phe-Tyr;1005496467;NC(CC1=CC=CC=C1)C(NC(CC2=CC=C(O)C=C2)C(O)=O)=O;NC(CC1=CC=CC=C1)C(NC(CC2=CC=C(O)C=C2)C(O)=O)=O;1.0;EC50=30mkM;1.0;100uM;IC50=20mkM;Glycylsarcosine;"rat in vivo; MDCK-PEPT1";"in vivo transport; efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM)";"M.Sato et al, J. Agric. Food Chem (2002) 9, 6245-52; B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44";;PEPT1;1
5306;Human;Ile-Trp;13589065;NC([C@@](CC)([H])C)C(NC(CC1=CNC2=C1C=CC=C2)C(O)=O)=O;NC([C@@](CC)([H])C)C(NC(CC1=CNC2=C1C=CC=C2)C(O)=O)=O;1.0; +;;100uM;;;in vivo;transport;M.Sato et al, J. Agric. Food Chem (2002) 9, 6245-52;;PEPT1;1
5307;Rat;4-Aminobutyrate;56122;NCCCC(=O)O;NCCCC(=O)O;0.0;Km>50mM (no transport);0.0;100uM;Ki=17.4mM;Glycylsarcosine;"Pichia pastoris cells and Xenopus oocytes/PEPT1; Caco-2";"transport; transport inhibition (Gly-Sar 10mkM)";"F.Doring et al, J Clin Invest (1998) 15,2761-67; S.Gebauer et al, J Med Chem (2003), 46(26), 5725-34";;PEPT1;0
5308;;5-Aminopentanoate;660888;NCCCCC(=O)O;NCCCCC(=O)O;1.0;Km=1.14mM (100% of control transport);;100uM;;;Pichia pastoris cells and Xenopus oocytes/PEPT1;transport;F.Doring et al, J Clin Invest (1998) 15,2761-67;;PEPT1;1
5309;;5-Amino-4-oxo-pentanoate;106605;NC(C=O)CCC(=O)O;NC(C=O)CCC(=O)O;1.0;"Km=0.27mM (100% of control transport); Km=1.6mM";;100uM;;;"Pichia pastoris cells and Xenopus oocytes/PEPT1; Xenopus oocytes/PEPT1";"transport; SYN: 5-Aminolevulinate";"F.Doring et al, J Clin Invest (1998) 15,2761-67; C.M.Anderson et al, J Pharmacol Exp Ther (2010) 332(1), 220-228";;PEPT1;1
5310;;Oseltamivir;196618130;O=C(OCC)/C1=C/[C@@H](OC(CC)CC)[C@H](NC(=O)C)[C@@H](N)C1;O=C(OCC)/C1=C/[C@@H](OC(CC)CC)[C@H](NC(=O)C)[C@@H](N)C1;1.0;Km=6.54-8.59mM;;100uM;;;Caco-2 and HeLa-PEPT1;transport;T.Ogihara et al, Drug Metab Dispos (2009), 37(8), 1676-1681;;PEPT1;1
5311;;Fosinopril;98048976;O=C(CP(=O)(CCCCc1ccccc1)OC(OC(=O)CC)C(C)C)N2C[C@@H](C[C@H]2C(O)=O)C3CCCCC3;O=C(CP(=O)(CCCCC1=CC=CC=C1)OC(OC(=O)CC)C(C)C)N2[C@@H](C[C@H](C2)C3CCCCC3)C(O)=O;1.0;Km=154mkM (permeability ratio (AB/BA) is ~3fold);1.0;100uM;Ki=35.5mkM (IC50=35.2mkM);Glycylsarcosine;Caco-2;GlySar (10mkM) uptake and inhibition of transport, Fosinopril (10mkM, stability was confirmed) intracellular accumulation and transport;C.Shu et al, Drug Metab Dispos (2001),29(10), 1307-1315;;PEPT1;1
5319;Human;Val-Phe;75946406;O=C(O)C(NC(=O)C(N)C(C)C)Cc1ccccc1;O=C(O)C(NC(=O)C(N)C(C)C)Cc1ccccc1;1.0;def.;1.0;100uM;Ki=50mkM;Glycylsarcosine;Caco-2;transport inhibition (Gly-Sar 10mkM);A.Biegel et al, J Med Chem(2005),48(13), 4410-9;;PEPT1;1
5322;Human;Asp-Asp;0;N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)O;N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)O;1.0;EC50=0.99mM;0.5;100uM;"Ki=0.41mM; IC50=0.63mM";"Glycylsarcosine; Glycylsarcosine";"Caco-2; MDCK-PEPT1";"transport inhibition (Gly-Sar 10mkM); efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM)";"A.Biegel et al, J Med Chem(2005),48(13), 4410-9; B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44";;PEPT1;1
5325;Human;Ala-Phe-Pro;0;C[C@H](N)C(=O)N[C@@H](Cc1ccccc1)C(=O)N2CCC[C@H]2C(=O)O;C[C@H](N)C(=O)N[C@@H](Cc1ccccc1)C(=O)N2CCC[C@H]2C(=O)O;1.0;def.;0.8;100uM;Ki=0.11mM;Glycylsarcosine;Caco-2;transport inhibition (Gly-Sar 10mkM);A.Biegel et al, J Med Chem(2005),48(13), 4410-9;;PEPT1;1
5327;Human;Leu-Thr-Leu;0;CC(C)C[C@H](N)C(=O)N(C)[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)O;CC(C)C[C@H](N)C(=O)N(C)[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)O;1.0;def.;0.8;100uM;Ki=0.11mM;Glycylsarcosine;Caco-2;transport inhibition (Gly-Sar 10mkM);A.Biegel et al, J Med Chem(2005),48(13), 4410-9;;PEPT1;1
5328;Human;Ala-Pro-Leu;0;CC(C)C[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)N)C(=O)O;CC(C)C[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)N)C(=O)O;1.0;def.;0.8;100uM;Ki=0.15mM;Glycylsarcosine;Caco-2;transport inhibition (Gly-Sar 10mkM);A.Biegel et al, J Med Chem(2005),48(13), 4410-9;;PEPT1;1
5329;Human;Leu-Arg-Pro;0;CC(C)C[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)O;CC(C)C[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)O;1.0;def.;0.5;100uM;Ki=0.3mM;Glycylsarcosine;Caco-2;transport inhibition (Gly-Sar 10mkM);A.Biegel et al, J Med Chem(2005),48(13), 4410-9;;PEPT1;1
5330;Human;Lys-Asp;0;NCCCC[C@H](N)C(=O)N[C@@H](CC(=O)O)C=O;NCCCC[C@H](N)C(=O)N[C@@H](CC(=O)O)C=O;1.0;def.;0.5;100uM;Ki=0.33mM;Glycylsarcosine;Caco-2;transport inhibition (Gly-Sar 10mkM);A.Biegel et al, J Med Chem(2005),48(13), 4410-9;;PEPT1;1
5331;Human;Ile-Val-Tyr;0;CC[C@H](C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)O;CC[C@H](C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)O;1.0;def.;0.5;100uM;Ki=0.2mM;Glycylsarcosine;Caco-2;transport inhibition (Gly-Sar 10mkM);A.Biegel et al, J Med Chem(2005),48(13), 4410-9;;PEPT1;1
5332;Human;Trp-Ala;0;C[C@H](NC(=O)[C@@H](N)Cc1c[nH]c2ccccc12)C(=O)O;C[C@H](NC(=O)[C@@H](N)Cc1c[nH]c2ccccc12)C(=O)O;1.0;EC50=0.1mM;0.5;100uM;"Ki=0.16mM; IC50=0.26mM";"Glycylsarcosine; Glycylsarcosine";"Caco-2; MDCK-PEPT1";"transport inhibition (Gly-Sar 10mkM); efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM)";"A.Biegel et al, J Med Chem(2005),48(13), 4410-9; B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44";;PEPT1;1
5333;Human;Ala-Ala-Ala;0;C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)O;C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)O;1.0;def.;0.5;100uM;Ki=0.18mM;Glycylsarcosine;Caco-2;transport inhibition (Gly-Sar 10mkM);A.Biegel et al, J Med Chem(2005),48(13), 4410-9;;PEPT1;1
5334;Human;Val-Ala-Leu;0;CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](N)C(C)C)C(=O)O;CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](N)C(C)C)C(=O)O;1.0;def.;0.8;100uM;Ki=0.14mM;Glycylsarcosine;Caco-2;transport inhibition (Gly-Sar 10mkM);A.Biegel et al, J Med Chem(2005),48(13), 4410-9;;PEPT1;1
5335;Human;Pro-Glu;0;OC(=O)CC[C@H](NC(=O)[C@@H]1CCCN1)C(=O)O;OC(=O)CC[C@H](NC(=O)[C@@H]1CCCN1)C(=O)O;0.0;EC50>5mM;0.0;100uM;"Ki=20mM; IC50=12.3mM";"Glycylsarcosine; Glycylsarcosine";"Caco-2; MDCK-PEPT1";"transport inhibition (Gly-Sar 10mkM); efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM)";"A.Biegel et al, J Med Chem(2005),48(13), 4410-9; B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44";;PEPT1;0
5336;Human;Ala-Cyclohexylamide;0;C[C@H](N)C(=O)NC(=O)C1CCCCC1;C[C@H](N)C(=O)NC(=O)C1CCCCC1;1.0;def.;0.5;100uM;Ki=1.5mM;Glycylsarcosine;Caco-2;transport inhibition (Gly-Sar 10mkM);A.Biegel et al, J Med Chem(2005),48(13), 4410-9;;PEPT1;1
5338;Human;Benzylphenylalanine-Ala;0;C[C@H](NC(=O)C(Cc1ccccc1)NCc2ccccc2)C(=O)O;C[C@H](NC(=O)C(Cc1ccccc1)NCc2ccccc2)C(=O)O;1.0;def.;1.0;100uM;Ki=0.02mM;Glycylsarcosine;Caco-2;transport inhibition (Gly-Sar 10mkM);A.Biegel et al, J Med Chem(2005),48(13), 4410-9;;PEPT1;1
5339;Human;Ala-Ser;0;C[C@H](N)C(=O)N[C@@H](CO)C(=O)O;C[C@H](N)C(=O)N[C@@H](CO)C(=O)O;1.0;def.;0.8;100uM;Ki=0.14mM;Glycylsarcosine;Caco-2;transport inhibition (Gly-Sar 10mkM);A.Biegel et al, J Med Chem(2005),48(13), 4410-9;;PEPT1;1
5340;Human;Ala-Orn;0;C[C@H](N)C(=O)NC(CCCN)C(=O)O;C[C@H](N)C(=O)NC(CCCN)C(=O)O;1.0;def.;0.0;100uM;Ki=0.97mM;Glycylsarcosine;Caco-2;transport inhibition (Gly-Sar 10mkM);A.Biegel et al, J Med Chem(2005),48(13), 4410-9;;PEPT1;1
5342;Human;Met-Met-Met;0;CSCC[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCSC)C(=O)O;CSCC[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCSC)C(=O)O;1.0;def.;1.0;100uM;Ki=0.1mM;Glycylsarcosine;Caco-2;transport inhibition (Gly-Sar 10mkM);A.Biegel et al, J Med Chem(2005),48(13), 4410-9;;PEPT1;1
5345;Human;Glu-Lys;0;NCCCC[C@H](NC(=O)[C@@H](N)CCC(=O)O)C(=O)O;NCCCC[C@H](NC(=O)[C@@H](N)CCC(=O)O)C(=O)O;1.0;EC50=0.31mM;0.0;100uM;"Ki=0.51mM; IC50=0.72mM";"Glycylsarcosine; Glycylsarcosine";"Caco-2; MDCK-PEPT1";"transport inhibition (Gly-Sar 10mkM); efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM)";"A.Biegel et al, J Med Chem(2005),48(13), 4410-9; B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44";;PEPT1;1
5346;Human;Val-Pro-Pro;0;CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N2CCC[C@H]2C(=O)O;CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N2CCC[C@H]2C(=O)O;1.0;def.;1.0;100uM;Ki=0.1mM;Glycylsarcosine;Caco-2;transport inhibition (Gly-Sar 10mkM);A.Biegel et al, J Med Chem(2005),48(13), 4410-9;;PEPT1;1
5348;Human;Pro-Asp;0;OC(=O)C[C@H](NC(=O)[C@@H]1CCCN1)C(=O)O;OC(=O)C[C@H](NC(=O)[C@@H]1CCCN1)C(=O)O;0.0;EC50>5mM;0.0;100uM;Ki=9.8mM;Glycylsarcosine;"Caco-2; MDCK-PEPT1";"transport inhibition (Gly-Sar 10mkM); efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM)";"A.Biegel et al, J Med Chem(2005),48(13), 4410-9; B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44";;PEPT1;0
5351;Human;Leu-Ala-Arg;0;CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O;CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O;1.0;def.;0.8;100uM;Ki=0.11mM;Glycylsarcosine;Caco-2;transport inhibition (Gly-Sar 10mkM);A.Biegel et al, J Med Chem(2005),48(13), 4410-9;;PEPT1;1
5352;Human;Phe-Leu-Leu;0;CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)Cc1ccccc1)C(=O)O;CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)Cc1ccccc1)C(=O)O;1.0;def.;0.8;100uM;Ki=0.14mM;Glycylsarcosine;Caco-2;transport inhibition (Gly-Sar 10mkM);A.Biegel et al, J Med Chem(2005),48(13), 4410-9;;PEPT1;1
5353;Human;Ile-Pro-Pro;0;CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N2CCC[C@H]2C(=O)O;CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N2CCC[C@H]2C(=O)O;1.0;def.;0.5;100uM;Ki=0.28mM;Glycylsarcosine;Caco-2;transport inhibition (Gly-Sar 10mkM);A.Biegel et al, J Med Chem(2005),48(13), 4410-9;;PEPT1;1
5355;Human;Tyr-Gly-Gly;0;N[C@@H](Cc1ccc(O)cc1)C(=O)NCC(=O)NCC(=O)O;N[C@@H](Cc1ccc(O)cc1)C(=O)NCC(=O)NCC(=O)O;1.0;def.;0.5;100uM;Ki=0.35mM;Glycylsarcosine;Caco-2;transport inhibition (Gly-Sar 10mkM);A.Biegel et al, J Med Chem(2005),48(13), 4410-9;;PEPT1;1
5356;Human;Ala-Phe-Leu;0;CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](C)N)C(=O)O;CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](C)N)C(=O)O;1.0;def.;1.0;100uM;Ki=0.1mM;Glycylsarcosine;Caco-2;transport inhibition (Gly-Sar 10mkM);A.Biegel et al, J Med Chem(2005),48(13), 4410-9;;PEPT1;1
5359;Human;Ser-Ala;0;C[C@H](NC(=O)[C@@H](N)CO)C(=O)O;C[C@H](NC(=O)[C@@H](N)CO)C(=O)O;1.0;def.;0.8;100uM;Ki=0.14mM;Glycylsarcosine;Caco-2;transport inhibition (Gly-Sar 10mkM);"A.Biegel et al, J Med Chem(2005),48(13), 4410-9; S.Gebauer et al, J Med Chem (2003), 46(26), 5725-34";;PEPT1;1
5360;Human;Leu-Gly-Gly;0;CC(C)C[C@H](N)C(=O)NCC(=O)NCC(=O)O;CC(C)C[C@H](N)C(=O)NCC(=O)NCC(=O)O;1.0;def.;0.5;100uM;Ki=0.39mM;Glycylsarcosine;Caco-2;transport inhibition (Gly-Sar 10mkM);A.Biegel et al, J Med Chem(2005),48(13), 4410-9;;PEPT1;1
5361;Human;Tyr-Ala;0;C[C@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)O;C[C@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)O;1.0;EC50=0.1mM;1.0;100uM;"Ki=0.09mM; IC50=0.11mM";"Glycylsarcosine; Glycylsarcosine";"Caco-2; MDCK-PEPT1";"transport inhibition (Gly-Sar 10mkM); efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM)";"A.Biegel et al, J Med Chem(2005),48(13), 4410-9; B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44";;PEPT1;1
5362;Human;Tyr-Pro-Ile;0;CCC(C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)O;CCC(C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)O;1.0;def.;0.5;100uM;Ki=0.25mM;Glycylsarcosine;Caco-2;transport inhibition (Gly-Sar 10mkM);A.Biegel et al, J Med Chem(2005),48(13), 4410-9;;PEPT1;1
5363;Human;Leu-Pro-Arg;0;CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(=O)O;CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(=O)O;1.0;def.;1.0;100uM;Ki=0.1mM;Glycylsarcosine;Caco-2;transport inhibition (Gly-Sar 10mkM);A.Biegel et al, J Med Chem(2005),48(13), 4410-9;;PEPT1;1
5364;Human;Glu-Phe-Tyr;0;N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)O;N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)O;1.0;def.;0.5;100uM;Ki=0.2mM;Glycylsarcosine;Caco-2;transport inhibition (Gly-Sar 10mkM);A.Biegel et al, J Med Chem(2005),48(13), 4410-9;;PEPT1;1
5365;Human;Thr-Lys-Tyr;0;C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)O;C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)O;1.0;def.;0.0;100uM;Ki=1.1mM;Glycylsarcosine;Caco-2;transport inhibition (Gly-Sar 10mkM);A.Biegel et al, J Med Chem(2005),48(13), 4410-9;;PEPT1;1
5367;Human;Trp-Gly-Tyr;0;N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCC(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)O;N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCC(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)O;1.0;def.;0.5;100uM;Ki=0.24mM;Glycylsarcosine;Caco-2;transport inhibition (Gly-Sar 10mkM);A.Biegel et al, J Med Chem(2005),48(13), 4410-9;;PEPT1;1
5368;Human;Lys-Glu;0;NCCCC[C@H](N)C(=O)N[C@@H](CCC(=O)O)C(=O)O;NCCCC[C@H](N)C(=O)N[C@@H](CCC(=O)O)C(=O)O;1.0;EC50=0.53mM;0.0;100uM;"Ki=1.3mM; IC50=0.82mM";"Glycylsarcosine; Glycylsarcosine";"Caco-2; MDCK-PEPT1";"transport inhibition (Gly-Sar 10mkM); efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM)";"A.Biegel et al, J Med Chem(2005),48(13), 4410-9; B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44";;PEPT1;1
5370;Human;Pro-Pro;0;OC(=O)[C@@H]1CCCN1C(=O)[C@@H]2CCCN2;OC(=O)[C@@H]1CCCN1C(=O)[C@@H]2CCCN2;1.0;EC50=0.7mM;0.0;100uM;"Ki=1.2mM; IC50=0.8mM";"Glycylsarcosine; Glycylsarcosine";"Caco-2; MDCK-PEPT1";"transport inhibition (Gly-Sar 10mkM); efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM)";"A.Biegel et al, J Med Chem(2005),48(13), 4410-9; B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44";;PEPT1;1
5371;Human;Cys-Gly;0;N[C@@H](CS)C(=O)NCC(=O)O;N[C@@H](CS)C(=O)NCC(=O)O;1.0;def.;0.5;100uM;Ki=0.2mM;Glycylsarcosine;Caco-2;transport inhibition (Gly-Sar 10mkM);A.Biegel et al, J Med Chem(2005),48(13), 4410-9;;PEPT1;1
5373;Human;Ser-Pro-Ile;0;CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CO)C(=O)O;CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CO)C(=O)O;1.0;def.;0.5;100uM;Ki=0.17mM;Glycylsarcosine;Caco-2;transport inhibition (Gly-Sar 10mkM);A.Biegel et al, J Med Chem(2005),48(13), 4410-9;;PEPT1;1
5374;Human;Phe-Ala;3918863;CC(NC(=O)C(N)Cc1ccccc1)C(=O)O;CC(NC(=O)C(N)Cc1ccccc1)C(=O)O;1.0;EC50=0.11mM;1.0;100uM;"Ki=0.11mM; IC50=70mkM; Ki=0.18mM";"Glycylsarcosine; Glycylsarcosine; Glycylsarcosine";"Caco-2; MDCK-PEPT1; Caco-2";"transport inhibition (Gly-Sar 10mkM); efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM); transepithelial transport and Gly-Sar (0.5mkCi) transport inhibition";"A.Biegel et al, J Med Chem(2005),48(13), 4410-9; S.Gebauer et al, J Med Chem (2003), 46(26), 5725-34; B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44; J.Vabeno et al, J Med Chem (2004), 47(4), 1060-9";;PEPT1;1
5375;Human;Trp-Trp-Trp;0;N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc3c[nH]c4ccccc34)C(=O)N[C@@H](Cc5c[nH]c6ccccc56)C(=O)O;N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc3c[nH]c4ccccc34)C(=O)N[C@@H](Cc5c[nH]c6ccccc56)C(=O)O;1.0;def.;0.5;100uM;Ki=0.17mM;Glycylsarcosine;Caco-2;transport inhibition (Gly-Sar 10mkM);A.Biegel et al, J Med Chem(2005),48(13), 4410-9;;PEPT1;1
5376;Human;Tyr-Phe;0;N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](Cc2ccccc2)C(=O)O;N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](Cc2ccccc2)C(=O)O;1.0;def.;1.0;100uM;Ki=0.09mM;Glycylsarcosine;Caco-2;transport inhibition (Gly-Sar 10mkM);"A.Biegel et al, J Med Chem(2005),48(13), 4410-9; S.Gebauer et al, J Med Chem (2003), 46(26), 5725-34";;PEPT1;1
5378;Human;Glu-Ala;0;C[C@H](NC(=O)[C@@H](N)CCC(=O)O)C(=O)O;C[C@H](NC(=O)[C@@H](N)CCC(=O)O)C(=O)O;1.0;def.;0.5;100uM;Ki=0.25mM;Glycylsarcosine;Caco-2;transport inhibition (Gly-Sar 10mkM);A.Biegel et al, J Med Chem(2005),48(13), 4410-9;;PEPT1;1
5380;Human;Gly-His;0;NCC(=O)N[C@@H](Cc1c[nH]cn1)C(=O)O;NCC(=O)N[C@@H](Cc1c[nH]cn1)C(=O)O;1.0;EC50=0.4mM;0.0;100uM;"Ki=1mM; IC50=0.81mM";"Glycylsarcosine; Glycylsarcosine";"Caco-2; MDCK-PEPT1";"transport inhibition (Gly-Sar 10mkM); efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM)";"A.Biegel et al, J Med Chem(2005),48(13), 4410-9; B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44; B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44";;PEPT1;1
5444;Human;Phe-Pro;0;NC(Cc1ccccc1)C(=O)N2CCCC2C(=O)O;NC(Cc1ccccc1)C(=O)N2CCCC2C(=O)O;1.0;def.;0.8;100uM;Ki=0.13mM;Glycylsarcosine;Caco-2;transport inhibition (Gly-Sar 10mkM);S.Gebauer et al, J Med Chem (2003), 46(26), 5725-34;;PEPT1;1
5448;Human;Glycine;56406;NCC(=O)O;NCC(=O)O;0.0; - (no activity);0.0;100uM; - at 10mM;Glycylsarcosine;MDCK-PEPT1;efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM);B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44;;PEPT1;0
5449;Human;Gly-Gly-Gly-Gly;0;NCC(NCC(NCC(NCC(O)=O)=O)=O)=O;NCC(NCC(NCC(NCC(O)=O)=O)=O)=O;0.0; - (no activity);0.0;100uM; - at 10mM;Glycylsarcosine;MDCK-PEPT1;efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM);B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44;;PEPT1;0
5450;Human;Gly-Tyr-NH2;0;NCC(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N;NCC(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N;0.0; - (no activity);0.0;100uM; - at 10mM;Glycylsarcosine;MDCK-PEPT1;efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM);B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44;;PEPT1;0
5452;Human;Valine;516063;NC(C(C)C)C(=O)O;NC(C(C)C)C(=O)O;0.0; - (no activity);0.0;100uM; - at 10mM;Glycylsarcosine;MDCK-PEPT1;efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM);B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44;;PEPT1;0
5453;Human;Tyr-Gly-NH2;0;N[C@@H](Cc1ccc(O)cc1)C(=O)NCC(=O)N;N[C@@H](Cc1ccc(O)cc1)C(=O)NCC(=O)N;0.0; - (no activity);0.0;100uM; - at 10mM;Glycylsarcosine;MDCK-PEPT1;efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM);B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44;;PEPT1;0
5454;Human;Tyr-Tic-NH2;0;N[C@@H](Cc1ccc(O)cc1)C(=O)N2CC3=CC=CC=C3CC2C(=O)N;N[C@@H](Cc1ccc(O)cc1)C(=O)N2CC3=CC=CC=C3CC2C(=O)N;0.0; - (no activity);0.0;100uM; - at 10mM;Glycylsarcosine;MDCK-PEPT1;efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM);B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44;;PEPT1;0
5455;Human;Orn-Orn;0;NC(CCCN)C(=O)NC(CCCN)C(=O)O;NC(CCCN)C(=O)NC(CCCN)C(=O)O;0.0; - (no activity);0.0;100uM; - at 10mM;Glycylsarcosine;MDCK-PEPT1;efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM);B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44;;PEPT1;0
5456;Human;Ac-Phe-Tyr-NH2;0;CC(=O)NC(CC1=CC=CC=C1)C(=O)NC(CC2=CC=C(O)C=C2)C(N)=O;CC(=O)NC(CC1=CC=CC=C1)C(=O)NC(CC2=CC=C(O)C=C2)C(N)=O;0.0; - (no activity);0.0;100uM; - at 10mM;Glycylsarcosine;MDCK-PEPT1;efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM);B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44;;PEPT1;0
5457;Human;Ac-Phe-di-iodo-Tyr;0;CC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N(I)I;CC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N(I)I;0.0; -(no activity);0.5;100uM;IC50=0.23mM;Glycylsarcosine;MDCK-PEPT1;efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM);B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44;;PEPT1;0
5458;Human;Ala-Phe;0;C[C@H](N)C(=O)N[C@@H](Cc1ccccc1)C(=O)O;C[C@H](N)C(=O)N[C@@H](Cc1ccccc1)C(=O)O;1.0;EC50=0.08mM;1.0;100uM;IC50=0.07mM;Glycylsarcosine;MDCK-PEPT1;efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM);B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44;;PEPT1;1
5459;Human;Ala-Trp;0;C[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O;C[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O;1.0;EC50=0.08mM;0.5;100uM;IC50=0.26mM;Glycylsarcosine;MDCK-PEPT1;efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM);B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44;;PEPT1;1
5460;Human;Ala-Tyr;0;C[C@H](N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)O;C[C@H](N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)O;1.0;EC50=0.06mM;0.8;100uM;"IC50=0.17mM; Ki=0.15mM";"Glycylsarcosine; Glycylsarcosine";"MDCK-PEPT1; Caco-2";"efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM); transport inhibition (Gly-Sar 10mkM)";"B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44; S.Gebauer et al, J Med Chem (2003), 46(26), 5725-34";;PEPT1;1
5461;Human;Arg-Arg;0;N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O;N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O;0.0; -(no activity);0.0;100uM;IC50=7.31mM;Glycylsarcosine;MDCK-PEPT1;efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM);B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44;;PEPT1;0
5462;Human;Arg-Gly;0;N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)O;N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)O;1.0;EC50=0.27mM;0.5;100uM;IC50=0.39mM;Glycylsarcosine;MDCK-PEPT1;efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM);B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44;;PEPT1;1
5463;Human;Arg-Lys;0;NCCCC[C@H](NC(=O)[C@@H](N)CCCN=C(N)N)C(=O)O;NCCCC[C@H](NC(=O)[C@@H](N)CCCN=C(N)N)C(=O)O;0.0; -(no activity);0.0;100uM;IC50=8.11mM;Glycylsarcosine;MDCK-PEPT1;efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM);B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44;;PEPT1;0
5464;Human;Asp-Trp;0;N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O;N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O;1.0;EC50=0.47mM;0.0;100uM;IC50=1.31mM;Glycylsarcosine;MDCK-PEPT1;efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM);B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44;;PEPT1;1
5465;Human;Asp-Val;0;CC(C)[C@H](NC(=O)[C@@H](N)CC(=O)O)C(=O)O;CC(C)[C@H](NC(=O)[C@@H](N)CC(=O)O)C(=O)O;1.0;EC50=0.69mM;0.5;100uM;IC50=0.31mM;Glycylsarcosine;MDCK-PEPT1;efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM);B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44;;PEPT1;1
5466;Human;Gln-Gln;0;N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O;N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O;1.0;EC50=0.1mM;0.8;100uM;IC50=0.15mM;Glycylsarcosine;MDCK-PEPT1;efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM);B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44;;PEPT1;1
5467;Human;Gln-Glu;0;N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O;N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O;1.0;EC50=0.42mM;0.0;100uM;IC50=0.51mM;Glycylsarcosine;MDCK-PEPT1;efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM);B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44;;PEPT1;1
5468;Human;Glu-Glu;0;N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)O;N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)O;1.0;EC50=1mM;0.0;100uM;IC50=0.62mM;Glycylsarcosine;MDCK-PEPT1;efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM);B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44;;PEPT1;1
5469;Human;Glu-Gly;0;N[C@@H](CCC(=O)O)C(=O)NCC(=O)O;N[C@@H](CCC(=O)O)C(=O)NCC(=O)O;1.0;EC50=0.51mM;0.5;100uM;IC50=0.39mM;Glycylsarcosine;MDCK-PEPT1;efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM);B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44;;PEPT1;1
5470;Human;Gly-Leu-Gly;0;CC(C)C[C@H](NC(=O)CN)C(=O)NCC(=O)O;CC(C)C[C@H](NC(=O)CN)C(=O)NCC(=O)O;1.0;EC50=0.21mM;0.5;100uM;IC50=0.24mM;Glycylsarcosine;MDCK-PEPT1;efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM);B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44;;PEPT1;1
5471;Human;Gly-Leu-Phe;0;CC(C)C[C@H](NC(=O)CN)C(=O)N[C@@H](Cc1ccccc1)C(=O)O;CC(C)C[C@H](NC(=O)CN)C(=O)N[C@@H](Cc1ccccc1)C(=O)O;1.0;EC50=0.28mM;0.0;100uM;IC50=0.98mM;Glycylsarcosine;MDCK-PEPT1;efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM);B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44;;PEPT1;1
5472;Human;Gly-Lys;0;NCCCC[C@H](NC(=O)CN)C(=O)O;NCCCC[C@H](NC(=O)CN)C(=O)O;1.0;EC50=0.75mM;0.0;100uM;IC50=1.25mM;Glycylsarcosine;MDCK-PEPT1;efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM);B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44;;PEPT1;1
5473;Human;Gly-Trp;0;NCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O;NCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O;1.0;EC50=0.33mM;0.0;100uM;IC50=0.52mM;Glycylsarcosine;MDCK-PEPT1;efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM);B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44;;PEPT1;1
5474;Human;Gly-Tyr;0;NCC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)O;NCC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)O;1.0;EC50=0.14mM;0.8;100uM;IC50=0.12mM;Glycylsarcosine;MDCK-PEPT1;efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM);B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44;;PEPT1;1
5475;Human;His-Gly;0;N[C@@H](Cc1c[nH]cn1)C(=O)NCC(=O)O;N[C@@H](Cc1c[nH]cn1)C(=O)NCC(=O)O;1.0;EC50=0.28mM;0.5;100uM;IC50=0.34mM;Glycylsarcosine;MDCK-PEPT1;efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM);B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44;;PEPT1;1
5476;Human;His-His;0;N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)O;N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)O;1.0;EC50=0.37mM;0.5;100uM;IC50=0.4mM;Glycylsarcosine;MDCK-PEPT1;efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM);B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44;;PEPT1;1
5477;Human;His-Trp;0;N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)O;N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)O;1.0;EC50=0.19mM;0.0;100uM;IC50=0.95mM;Glycylsarcosine;MDCK-PEPT1;efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM);B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44;;PEPT1;1
5478;Human;Lys-Arg;0;NCCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O;NCCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O;0.0; -(no activity);0.0;100uM;IC50=7.2mM;Glycylsarcosine;MDCK-PEPT1;efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM);B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44;;PEPT1;0
5479;Human;Lys-Gly;0;NCCCC[C@H](N)C(=O)NCC(=O)O;NCCCC[C@H](N)C(=O)NCC(=O)O;1.0;EC50=0.32mM;0.5;100uM;IC50=0.38mM;Glycylsarcosine;MDCK-PEPT1;efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM);B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44;;PEPT1;1
5480;Human;Lys-Lys;0;NCCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)O;NCCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)O;0.0; -(no activity);0.0;100uM;IC50=10.9mM;Glycylsarcosine;MDCK-PEPT1;efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM);B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44;;PEPT1;0
5481;Human;Lys-Trp;0;NCCCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O;NCCCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O;0.0; -(no activity);0.0;100uM;IC50=0.66mM;Glycylsarcosine;MDCK-PEPT1;efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM);B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44;;PEPT1;0
5482;Human;Lys-Val;0;CC(C)[C@H](NC(=O)[C@@H](N)CCCCN)C(=O)O;CC(C)[C@H](NC(=O)[C@@H](N)CCCCN)C(=O)O;1.0;EC50=0.14mM;0.5;100uM;IC50=0.25mM;Glycylsarcosine;MDCK-PEPT1;efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM);B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44;;PEPT1;1
5483;Human;Phe-Ala-NH2;0;C[C@H](NC(=O)[C@@H](N)Cc1ccccc1)C(=O)N;C[C@H](NC(=O)[C@@H](N)Cc1ccccc1)C(=O)N;1.0;EC50=0.85mM;0.0;100uM;IC50=2.99mM;Glycylsarcosine;MDCK-PEPT1;efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM);B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44;;PEPT1;1
5484;Human;Phe-Gly;0;N[C@@H](Cc1ccccc1)C(=O)NCC(=O)N;N[C@@H](Cc1ccccc1)C(=O)NCC(=O)N;1.0;EC50=0.11mM;0.5;100uM;"IC50=0.17mM; Ki=0.20mM";"Glycylsarcosine; Glycylsarcosine";"MDCK-PEPT1; Caco-2";"efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM); transepithelial transport and Gly-Sar (0.5mkCi) transport inhibition";"B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44; J.Vabeno et al, J Med Chem (2004), 47(4), 1060-9";;PEPT1;1
5485;Human;Pro-Gly;0;OC(=O)CNC(=O)[C@@H]1CCCN1;OC(=O)CNC(=O)[C@@H]1CCCN1;0.0; -(no activity);0.0;100uM;"IC50>16mM; Ki=22mM";"Glycylsarcosine; Glycylsarcosine";"MDCK-PEPT1; Caco-2";"efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM); transport inhibition (Gly-Sar 10mkM)";"B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44; S.Gebauer et al, J Med Chem (2003), 46(26), 5725-34";;PEPT1;0
5486;Human;Pro-Leu;0;CC(C)C[C@H](NC(=O)[C@@H]1CCCN1)C(=O)O;CC(C)C[C@H](NC(=O)[C@@H]1CCCN1)C(=O)O;1.0;EC50=0.25mM;0.5;100uM;"IC50=0.62mM; Ki=0.47mM";"Glycylsarcosine; Glycylsarcosine";"MDCK-PEPT1; Caco-2";"efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM); transport inhibition (Gly-Sar 10mkM)";"B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44; S.Gebauer et al, J Med Chem (2003), 46(26), 5725-34";;PEPT1;1
5487;Human;Pro-Lys;0;NCCCC[C@H](NC(=O)[C@@H]1CCCN1)C(=O)O;NCCCC[C@H](NC(=O)[C@@H]1CCCN1)C(=O)O;0.0; -(no activity);0.0;100uM;IC50>16mM;Glycylsarcosine;MDCK-PEPT1;efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM);B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44;;PEPT1;0
5488;Human;Pro-Ser;0;OC[C@H](NC(=O)[C@@H]1CCCN1)C(=O)O;OC[C@H](NC(=O)[C@@H]1CCCN1)C(=O)O;1.0;EC50=1.6mM;0.0;100uM;"IC50>16mM; Ki=14mM";"Glycylsarcosine; Glycylsarcosine";"MDCK-PEPT1; Caco-2";"efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM); transport inhibition (Gly-Sar 10mkM)";"B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44; S.Gebauer et al, J Med Chem (2003), 46(26), 5725-34";;PEPT1;1
5489;Human;Ser-Ser;0;N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O;N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O;1.0;EC50=0.14mM;0.8;100uM;IC50=0.13mM;Glycylsarcosine;MDCK-PEPT1;efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM);B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44;;PEPT1;1
5490;Human;Trp-Gly;0;N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCC(=O)O;N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCC(=O)O;1.0;EC50=0.26mM;0.0;100uM;IC50=0.73mM;Glycylsarcosine;MDCK-PEPT1;efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM);B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44;;PEPT1;1
5491;Human;Trp-Trp;0;N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc3c[nH]c4ccccc34)C(=O)O;N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc3c[nH]c4ccccc34)C(=O)O;0.0; -(no activity);0.5;100uM;IC50=0.25mM;Glycylsarcosine;MDCK-PEPT1;efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM);B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44;;PEPT1;0
5492;Human;Trp-Tyr;0;N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)O;N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)O;0.0; -(no activity);1.0;100uM;IC50=0.08mM;Glycylsarcosine;MDCK-PEPT1;efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM);B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44;;PEPT1;0
5493;Human;Trp-Val;0;CC(C)[C@H](NC(=O)[C@@H](N)Cc1c[nH]c2ccccc12)C(=O)O;CC(C)[C@H](NC(=O)[C@@H](N)Cc1c[nH]c2ccccc12)C(=O)O;1.0;EC50=0.05mM;1.0;100uM;IC50=0.09mM;Glycylsarcosine;MDCK-PEPT1;efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM);B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44;;PEPT1;1
5494;Human;Tyr-Gly;0;N[C@@H](Cc1ccc(O)cc1)C(=O)NCC(=O)O;N[C@@H](Cc1ccc(O)cc1)C(=O)NCC(=O)O;1.0;EC50=0.24mM;0.5;100uM;IC50=0.33mM;Glycylsarcosine;MDCK-PEPT1;efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM);B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44;;PEPT1;1
5495;Human;Tyr-Trp;0;N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)O;N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)O;0.0; -(no activity);1.0;100uM;IC50=0.1mM;Glycylsarcosine;MDCK-PEPT1;efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM);B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44;;PEPT1;0
5496;Human;Tyr-Tyr;0;N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)O;N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)O;1.0;EC50=0.06mM;1.0;100uM;IC50=0.06mM;Glycylsarcosine;MDCK-PEPT1;efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM);B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44;;PEPT1;1
5497;Human;Tyr-Tyr-NH2;0;N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N;N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N;0.0; -(no activity);0.0;100uM;IC50=9.11mM;Glycylsarcosine;MDCK-PEPT1;efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM);B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44;;PEPT1;0
5498;Human;Val-Trp;0;CC(C)[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O;CC(C)[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O;1.0;EC50=0.04mM;1.0;100uM;IC50=0.1mM;Glycylsarcosine;MDCK-PEPT1;efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM);B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44;;PEPT1;1
5499;Human;Val-Val;0;CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)O;CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)O;1.0;EC50=0.07mM;0.5;100uM;IC50=0.21mM;Glycylsarcosine;MDCK-PEPT1;efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM);B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44;;PEPT1;1
5500;Human;Val-Val-Val;0;CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)O;CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)O;1.0;EC50=0.21mM;0.5;100uM;IC50=0.23mM;Glycylsarcosine;MDCK-PEPT1;efflux by membrane depolarization - EC50 (Km-like), transport inhibition (Gly-Sar 10mkM);B.S.Vig et al, J Med Chem (2006), 49(12), 3636-44;;PEPT1;1
5515;Human;CHEMBL189248;0;CC(C)[C@H](N)C(=O)CCC(=O)OCc1ccccc1;CC(C)[C@H](N)C(=O)CCC(=O)OCc1ccccc1;0.8; + (ester unstable);0.8;100uM;Ki=133mkM;Glycylsarcosine;Caco-2;transepithelial transport and Gly-Sar (0.5mkCi) transport inhibition;J.Vabeno et al, J Med Chem (2004), 47(19), 4755-65;;PEPT1;1
5516;Human;CHEMBL189777;0;N[C@@H](Cc1ccccc1)C(=O)C[C@@H](CC(=O)OCc2ccccc2)C(=O)O;N[C@@H](Cc1ccccc1)C(=O)C[C@@H](CC(=O)OCc2ccccc2)C(=O)O;1.0; + at 1mM;1.0;100uM;Ki=68mkM;Glycylsarcosine;Caco-2;transepithelial transport and Gly-Sar (0.5mkCi) transport inhibition;J.Vabeno et al, J Med Chem (2004), 47(19), 4755-65;;PEPT1;1
5517;Human;CHEMBL434541;0;NC(CC(=O)OCc1ccccc1)C(=O)CCC(=O)O;NC(CC(=O)OCc1ccccc1)C(=O)CCC(=O)O;1.0; + at 1mM;0.0;100uM;Ki=19mkM ;Glycylsarcosine;Caco-2;transepithelial transport and Gly-Sar (0.5mkCi) transport inhibition;J.Vabeno et al, J Med Chem (2004), 47(19), 4755-65;;PEPT1;1
5518;Human;CHEMBL188947;0;CC(C)[C@H](N)C(=O)C[C@@H](CC(=O)OCc1ccccc1)C(=O)O;CC(C)[C@H](N)C(=O)C[C@@H](CC(=O)OCc1ccccc1)C(=O)O;1.0; + at 1mM;0.5;100uM;Ki=417mkM;Glycylsarcosine;Caco-2;transepithelial transport and Gly-Sar (0.5mkCi) transport inhibition;J.Vabeno et al, J Med Chem (2004), 47(19), 4755-65;;PEPT1;1
5519;Human;CHEMBL10650;68709773;N[C@@H](Cc1ccccc1)C(=O)CCC(=O)O;N[C@@H](Cc1ccccc1)C(=O)CCC(=O)O;1.0; + at 0.5mM;0.5;100uM;Ki=0.4mM;Glycylsarcosine;Caco-2;transepithelial transport and Gly-Sar (0.5mkCi) transport inhibition;J.Vabeno et al, J Med Chem (2004), 47(4), 1060-9;;PEPT1;1
5520;Human;CHEMBL10717;0;N[C@@H](Cc1ccccc1)C(O)\C=C\C(=O)O;N[C@@H](Cc1ccccc1)C(O)\C=C\C(=O)O;0.0; - at 0.5mM;0.0;100uM;Ki=26.4mM (CASRN:521064-18-6) and Ki=39.8mM (CASRN:521064-19-7);Glycylsarcosine;Caco-2;transepithelial transport and Gly-Sar (0.5mkCi) transport inhibition;J.Vabeno et al, J Med Chem (2004), 47(4), 1060-9;;PEPT1;0
5522;Human;Ile-3-HPG;0;CC[C@H](C)[C@H](N)C(=O)OCc1cccc(NC(=N)N)c1;CC[C@H](C)[C@H](N)C(=O)OCc1cccc(NC(=N)N)c1;1.0; + at 1mM;0.0;100uM;IC50=0.63mM;Glycylsarcosine;HeLa/PEPT1 and Caco-2;uptake (1mM) and inhibition of Gly-Sar (10mkM) uptake;J.Sun et al, J Med Chem (2010), 53(2), 624-632;;PEPT1;1
5523;Human;3-(hydroxymethyl)-phenylguanidine (3-HPG);0;NC(=N)Nc1cccc(CO)c1;NC(=N)Nc1cccc(CO)c1;0.0;1.4-fold uptake increase at 1mM (HeLa vs HeLa/PEPT1);0.0;100uM;IC50>3mM;Glycylsarcosine;HeLa/PEPT1 and Caco-2;uptake (1mM) and inhibition of Gly-Sar (10mkM) uptake;J.Sun et al, J Med Chem (2010), 53(2), 624-632;;PEPT1;0
5524;Human;L-Val-3-HPG;0;CC(C)[C@H](N)C(=O)OCc1cccc(NC(=N)N)c1;CC(C)[C@H](N)C(=O)OCc1cccc(NC(=N)N)c1;1.0; + at 1mM;0.0;100uM;IC50=0.65mM;Glycylsarcosine;HeLa/PEPT1 and Caco-2;uptake (1mM) and inhibition of Gly-Sar (10mkM) uptake;J.Sun et al, J Med Chem (2010), 53(2), 624-632;;PEPT1;1
5527;Human;Phe-3-HPG;0;N[C@@H](Cc1ccccc1)C(=O)OCc2cccc(NC(=N)N)c2;N[C@@H](Cc1ccccc1)C(=O)OCc2cccc(NC(=N)N)c2;1.0; + at 1mM;0.0;100uM;IC50=2.33mM;Glycylsarcosine;HeLa/PEPT1 and Caco-2;uptake (1mM) and inhibition of Gly-Sar (10mkM) uptake;J.Sun et al, J Med Chem (2010), 53(2), 624-632;;PEPT1;1
5529;Human;QSP;0;N[C@@H](CCC(=O)N)C(=O)N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)O;N[C@@H](CCC(=O)N)C(=O)N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)O;1.0;Km=4.2mM;;100uM;;;Xenopus laevis oocyte/PEPT1;uptake (by membrane depolarization);A.Vernaleken et al, J Biol Chem (2007),282(39),28501-13;;PEPT1;1
5530;Human;QCPac;0;C[C@H](NC(=O)[C@@H]1CCCN1C(=O)C)C(=O)N[C@@H](CS)C(=O)O;C[C@H](NC(=O)[C@@H]1CCCN1C(=O)C)C(=O)N[C@@H](CS)C(=O)O;1.0;Km=21.4mM;;100uM;;;Xenopus laevis oocyte/PEPT1;uptake (by membrane depolarization);A.Vernaleken et al, J Biol Chem (2007),282(39),28501-13;;PEPT1;1
5531;Human;PCQac;0;CC(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CS)C(=O)N1CCC[C@H]1C(=O)O;CC(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CS)C(=O)N1CCC[C@H]1C(=O)O;1.0; + at 5mM;;100uM;;;Xenopus laevis oocyte/PEPT1;uptake (by membrane depolarization);A.Vernaleken et al, J Biol Chem (2007),282(39),28501-13;;PEPT1;1
5532;Human;Tebipenem pivoxil;161715248;CC1C2C(C(=O)N2C(=C1SC3CN(C3)C4=NCCS4)C(=O)OCOC(=O)C(C)(C)C)C(C)O;O=C(OCOC(=O)C=4N1C(=O)[C@H]([C@H](O)C)[C@H]1[C@H](C=4SC3CN(C2=NCCS2)C3)C)C(C)(C)C;0.0; - at 100mkM;;100uM;;;Oocytes;uptake (100mkM);K.Kato et al, Mol Pharmaceutics (2010) 7(5), 1747-56;;PEPT1;0
